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Abstract 
Obesity is a highly prevalent disease associated with a number of chronic and 
noncommunicable diseases including type 2 diabetes (T2D), nonalcoholic fatty liver 
disease (NAFLD), and cardiovascular disease (CVD). Obesity is associated with a 
chronic low-grade systemic inflammation, which is thought to cause insulin resistance 
as well as other co-morbidities. The systemic inflammation may originate in the 
adipose tissue (AT), and is characterized by an infiltration of immune cells into the 
tissue and paracrine and endocrine secretion of pro-inflammatory cytokines. Adipose 
tissue macrophages and NK cells has previously been shown to be important for 
obesity-associated AT inflammation, and NK cells have also been linked to liver 
inflammation in mice models of (NASH). 
In paper I, we investigated circulating NK cells in patients with NAFLD and NASH 
and found that the proportions of CD56dim to CD56bright NK cells were similar to healthy 
controls. Further, NK cells from patients and healthy controls showed similar 
expression levels of activating and inhibitory receptors, with the exception of NK cells 
from patients with NASH, which showed increased expression of the activating 
receptor NKG2D. NK cells from NAFLD and NASH patients also had retained 
functionality compared to healthy controls, and the frequency of liver and AT NK cells 
were unaltered in the patients. 
In paper II, we characterized ATMs in individuals with obesity, and found that the 
visceral adipose tissue (VAT) harboured relatively more pro-inflammatory M1-like 
macrophages than the subcutaneous visceral tissue (SAT). The pro-inflammatory ratio 
between M1- and M2-like ATMs correlated positively with the degree of insulin 
resistance and dyslipidemia. For other markers of inflammation, such as expression of 
inflammatory genes or the numbers of crown-like structures in the AT, we did not find 
any signficant associations with the metabolic disease parameters. Interestingly, 
improved insulin sensitivity after weight loss following bariatric surgery was not 
correlated to a simultaneous decrease in circulating inflammatory factors, suggesting 
that these two events were not linked.  
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Lastly, in paper III we characterized the surface proteome of ATMs and adipocyte 
progenitor cells (APCs) and found subpopulations of the macrophages and progenitors 
with distinct expression of surface proteins. We compared our surface protein data with 
an available scRNA-seq dataset, and found enrichment of both ATM and APC-specific 
markers in macrophage and progenitor clusters. We also used the scRNA-seq data to 
explore the local interactome of the macrophage and progenitor cells in adipose tissue, 
using a computational method guided by our surface protein expression data.  
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1.1.1 Definition and prevalence 
Obesity is considered a major global health problem with increased risk of developing 
co-morbidities such as insulin resistance and type 2 diabetes (T2D), cardiovascular 
disease (CVD), nonalcoholic fatty liver disease (NAFLD) and certain cancers. Obesity 
is also associated with increased mortality compared to normal weight (1), also 
independently of physical activity levels (2). According to the World Health 
Organization (WHO), the rate of worldwide obesity has almost tripled since 1975, 
while the prevalence of obesity in Norway had nearly doubled between 1980 and 2015 
(3). The WHO stated that in 2016 more than 650 million adults worldwide were defined 
as being obese, with estimates of more than 1.12 billion obese individuals by 2030. 
Further, 1.9 billion adults were classified as being overweight in 2016 (4). 
WHO defines obesity and overweight as excessive accumulation of fat that may have 
negative impact on health. Body mass index (BMI) is a common way to measure 
obesity and overweight and is calculated by dividing the weight of an individual in 
kilograms by the square of its height measure in meters (kg/m2). For adults, overweight 
and obesity is classified as having a BMI of 25 and above and 30 and above respectively 
(5). Further obesity is classified into three categories depending on BMI (Table 1). 
The risk of comorbidities is expected to increase with increasing BMI and even 
moderate weight gain in adults are shown to be associated with a higher risk of death 
(2), which is also true for people characterized as overweight (6,7). BMI is a useful 
measure of obesity on a population level; however, it does not take into account the 
distribution of body fat nor if a higher weight is due to increased muscle mass rather 
than increased fat mass. Thus, individuals with the same BMI may not have the same 




Table 1: Obesity classification according to BMIa 
Classification BMI (kg/m2) 
Underweight < 18.5 
Normal range 18.50 – 24.99 
Overweight ≥ 25.00 
Preobese 25.00 – 29.99 
Obese class I 30.00 – 34.99 
Obese class II 35.00 – 39.99 
Obese class III ≥ 40.00 
 aAccording to WHO (reference, fact sheet) 
As increased fat accumulation in the abdominal region is associated with increased risk 
of obesity-related co-morbidities (8) the waist circumference (WC) or the waist-to-hip 
ratio (WHR) has been suggested as alternative measures to determine obesity and risk 
for comorbidities. The WHR is found to predict diabetes and CVD better than BMI 
(9,10), and WC is also considered one of the parameters defining the metabolic 
syndrome (11). WC, rather than BMI, was also found to predict obesity-associated co-
morbidities. Consequently, similar health risk was seen for individuals with the same 
WC regardless of whether they were defined as lean, overweight or obese according to 
their BMI (12). Additionally, the waist-to-height ratio is also used to predict risk of 
obesity-related diseases and had been shown to be better predictors of CVD and T2D 
than BMI (13). Additionally, increased body fat percentage is seen in individuals with 
prediabetes or T2D that are considered lean according to their BMI. However, BMI is 
still widely used as inclusion criteria in for instance clinical studies or to be eligible for 
obesity treatment with bariatric surgery (14). 
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1.1.2 Comorbidities of obesity 
Obesity is associated with a number of comorbidities, including CVD, NAFLD, T2D, 
and several types of cancer. The metabolic syndrome is a term used to describe a 
combination of metabolic disturbances associated with obesity. It was first described 
in the 1920’s and has been defined in various ways later. However, the current 
definition describes it as cardiovascular risk factors that is associated with a high risk 
of developing T2D. The International Diabetes Federation had defined the metabolic 
syndrome as the presence of central obesity as well as the occurrence of two or more 
of the following: elevated levels of triglycerides (≥ 1.7 mmol/L), decreased levels of 
HDL-cholesterol (< 1.03 mmol/L in males and <1.29 mmol/L in females), elevated 
blood pressure (≥ 130 mmHg systolic or ≥ 85 mmHg diastolic) or increased fasting 
blood glucose levels (≥ 5.6 mml/L or previously diagnosed T2D) (15). 
 
Cardiovascular disease 
Obesity is known to increase the risk of CVD, and weight gain may increase the risk 
of death from CVD (2). Cytokines and other inflammatory factors secreted by adipose 
tissue during obesity can affect blood lipid levels and promote atherosclerosis. Visceral 
adiposity is associated with CVD (16), hypertension, (17) and higher levels of 
plasminogen activator inhibitor-1 (PAI-1), which is a pro-coagulant. Further fat storage 
in other places than the AT, such as in the heart, blood vessel,s and kidneys has been 
found to increase CVD risk (18). 
Accumulation of abdominal fat is associated with increased CVD risk as both the WC 
and WHR are independently associated with an increased risk of coronary heart 
disease. Obesity is also associated with increased levels of leptin, which can induce 
platelet aggregation and arterial thrombosis (19). Increased leptin levels are also linked 
to impairments in vascular functions (20). Low levels of adiponectin, which is seen in 
obese individuals, has also been associated with impaired vasodilation (21). Thus, the 
circulating levels of the adipokines leptin and adiponectin might be a link between 
obesity and CVD. 
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Dyslipidemia, hypertension, and glucose dysmetabolism is thought to be obesity-
induced factors that can increase the risk for cardiovascular disease. Further, 
adipokines, pro-inflammatory cytokines, and fibrinolytic factors secreted from 
adipocytes or adipose tissue macrophages might also increase oxidative stress and 
endothelial dysfunction, which in turn can lead to atherosclerosis (22). 
Type 2 diabetes and insulin resistance 
Obesity is a major risk factor for development of T2D and insulin resistance. Diabetes 
is a disease characterized by elevated levels of blood glucose. The two major forms of 
diabetes are type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D is an autoimmune 
disease where the insulin-producing β cells in the pancreas is destroyed leading to 
insulin deficiency. T2D, on the other hand, is a multifactorial disease which is 
characterized by a combination of insulin resistance and pancreatic β cell failure. The 
insulin resistance leads to higher levels of insulin being secreted by the pancreatic β 
cells, which compensates for the lack of responsiveness to insulin in the tissues and 
maintain normal or almost normal glucose levels. Eventually, the β cells start to fail 
and can no longer secrete high enough amounts of insulin, leading to hyperglycemia 
and T2D (23). 
The prevalence of diabetes is thought to be about 463 million people and is estimated 
to increase to about 578 million by 2030. T2D accounts for around 90 % of diabetes 
cases worldwide. At the same time, half of the world’s 493 individuals with T2D are 
unaware of their condition (24). WHO recommends four ways to diagnose diabetes and 
those include: fasting plasma glucose values ≥7.0 mmol/L, plasma glucose ≥11.1 
mol/L 2 hours after glucose load, HbA1c ≥48 mmol/mol (6.5%) or a random blood 
glucose ≥11.1 mmol/L in the presence of symptoms of diabetes (25). HbA1c is 
glycosylated hemoglobin and reflects the average blood glucose levels the past 8 to 12 
weeks (26). 
Prediabetes is characterized by impaired glucose tolerance and/or impaired fasting 
glucose and is a risk factor for development of T2D (26). WHO defines impaired 
glucose tolerance as fasting plasma glucose of < 7.0 mmol/l or 2-hour plasma glucose 
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≥7.8 and < 11.1 mmol/L and impaired fasting glucose as both a fasting glucose level 
between 6.1 and 6.9 mmol/L and a 2-hour plasma glucose of <7.8 mmol/L. Further, 
the American Diabetes Association also includes HbA1c between 39 and 47 (5.7-6.4%) 
in their criteria for prediabetes (26). Diabetes is a risk factor for CVD through 
mechanisms such as insulin resistance, inflammation, and endothelial dysfunctions. 
Further high blood glucose levels can have toxic effects om microvasculature. 
Insulin resistance occurs when a normal dose of insulin cannot stimulate its regular 
responses thereby decreasing insulin signaling. This leads to a reduction in insulin 
sensitivity. In the adipose tissue, insulin resistance leads to increased lipolysis, 
stimulating re-esterification of lipids in other tissues, such as muscle and liver, further 
worsening the insulin resistance. Lipid accumulation in muscle cells can impair glucose 
uptake resulting in increased glucose to the liver, while in the liver, lipid accumulation 
reduces the capacity of insulin to activate glycogen synthesis and regulate 
gluconeogenesis (27). 
Insulin resistance can be assessed using the hyperinsulinemic-euglycemic clamp 
technique, which is considered the gold standard method to measure insulin sensitivity. 
This technique involves insulin being administered intravenously at a constant rate. 
Subsequently, glucose is intravenously infused to maintain fasting levels of glucose in 
the blood. Thus, the amount of glucose infused is equivalent to the amount of glucose 
needed to compensate for the hyperinsulinemia. The steady-state glucose infusion rate 
then reflects the level of insulin sensitivity (28,29). The hyperinsulinemic-euglycemic 
clamp technique is a complicated and labor-intensive way to measure insulin 
resistance. Thus, the homeostatic model assessment of insulin resistance (HOMA-IR) 
is frequently used as a more feasible alternative to measure insulin resistance in larger 
cohorts. This method, first described in 1985 (30), uses fasting glucose and insulin 
levels (measured in mmol/L) to determine insulin resistance and β-cell function (%B), 
which can be measured using simple formulas: HOMA-IR = (FPI x FPG)/22.5 and 
HOMA%B (20 x FPI) / (FPG – 3.5), where FPI and FPG is fasting plasma insulin and 
fasting plasma glucose respectively (31). Later a computer model was developed to 
more accurately determine HOMA-IR and β-cell function using fasting plasma glucose 
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and fasting plasma insulin or C-peptide levels across a range of 1-2200 pmol/L for 
insulin and 1-25 mmol/L for glucose (32). Currently, no cut-off values for HOMA-IR 
has been set to define insulin resistance. 
Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis 
NAFLD is the most common chronic liver disease with a prevalence of about 24 % in 
2016 (33). NAFLD can progress to a more severe form of liver disease, non-alcoholic 
steatohepatitis (NASH), with the risk of developing liver cirrhosis, liver failure, and 
hepatocellular carcinoma (HCC) (34). Development of NAFLD is driven by a 
combination of genetic and environmental factors and is linked to obesity and the 
metabolic syndrome. There is currently no effective medication against NAFLD (35), 
and it is thought that this disease will become the primary cause of liver transplantation 
in the coming years (36). Progression to NASH might involve reduced hepatic levels 
of neuregulin 4, a factor secreted by adipocytes. Further, type II inflammatory 
responses involving transforming growth factor β (TGFβ) is thought to promote 
fibrosis in NAFLD. Patients with NASH fibrosis is found to have more IgA+ plasma 
cells in their liver relative to patients without NASH fibrosis. These cells may inhibit 
CD8+ T cell activity leading to increased risk of HCC (35). 
1.1.3 Treatment of obesity 
Lifestyle interventions 
The WHO recommend a weight loss of 10% in order to improve health and reduce co-
morbidities (37). Traditional treatment of obesity is lifestyle interventions, including 
diet, exercise, and behavior therapy. However, while some studies have shown 
substantial weight loss for obese individuals undergoing weight-loss interventions, a 
meta-analysis showed that most studies reported a weight loss less than 5% with little 
or no beneficial effects on metabolic parameters (38). 
Pharmacological treatment 
Pharmacological treatment of obesity is often a supplement to lifestyle interventions 
leading to additional weight loss. Many drugs used in the treatment of obesity is 
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affecting hunger and satiety. In Norway there are currently three drugs approved for 
treating obesity: liraglutide, orlistat, and combination of naltrexone and bupropion (39). 
Liraglutide is a GLP-1 analogue primarily used in treatment of T2D. GLP-1 is a peptide 
hormone that is involved in appetite control and liraglutide is thought to decrease 
appetite and thereby reduce food intake. Orlistat is a lipase inhibitor and works by 
reducing the absorption of fats from the diet in the intestine. This drug is also found to 
reduce blood pressure, insulin resistance, and blood lipids. Naltrexone is an opioid 
receptor agonist also used in the treatment of alcohol and opioid dependence. 
Bupropion inhibits dopamine and norepinephrine transporters and is used in treatment 
of depression. These drugs are used in combination; however, their exact mechanism 
of action with respect to weight loss is unclear. It is thought that the combination 
increases the activity of the POMC neurons in the hypothalamus leading to both 
decreased food intake and increased energy expenditure (40). 
Bariatric surgery 
Bariatric surgery is considered the most effective treatment option for morbid obesity. 
The initial weight loss following bariatric surgery is usually quite large with the 
maximum weight loss seen during the first year after surgery, often followed by a 
subsequent increase in weight (41). The Swedish Obese Subjects (SOS) study 
involving 2010 bariatric surgery patients report a mean reduction in body weight at 
23% after 2 years, and after 10, 15, and 20 years the mean reduction in body weight 
was 17%, 16% and 18% respectively. At the same time bariatric surgery was associated 
with an overall reduction in mortality and fewer cases of T2D, CVD, and cancer 
compared with an obese control group (42). Inclusion criteria for bariatric surgery in 
Norway is BMI>40 or BMI>35 with co-morbidites, such as T2D and hypertension 
(43). 
Bariatric surgery reduces the size of the stomach and/or changes the anatomy of the 
gastrointestinal tract. The most commonly used procedures include sleeve gastrectomy 
and Roux-en-Y gastric bypass, with the latter associated with the best long-term 
outcomes for T2D remission (44) and a rapid improvement in postprandial glucose 
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homeostasis after surgery (45) Additionally, insulin sensitivity, measured by HOMA-
IR, is found to decrease within days after surgery (46). The mechanisms involved in 
the weight loss effect of these procedures are both restrictive and/or malabsorptive. 
Roux-en-Y gastric bypass uses a combination of restriction and malabsorption. It 
includes disconnection of a large part of the stomach to create a small gastric pouch. 
Further, the small intestine is divided and the distal portion is connected to the gastric 
pouch. The lower portion of the stomach with the upper part of the intestine attached 
is then connected further down on the small intestine to allow pancreatic and biliary 
secretes to come in contact with the food passing through. Sleeve gastrectomy is a 
procedure where a large portion of the stomach is removed, leaving only a small tube 
of stomach left (47). 
A remarkable feature of bariatric surgery is that most patients with T2D experience 
remission within days to weeks after the surgery, before any weight loss has occurred 
(48). Bariatric surgery patients are found to be more likely to undergo remission of 
hypertension, diabetes, and dyslipidemia compared to obese patients undergoing 
medical treatment, including lifestyle intervention. At the same time, surgery patients 
also had a lower risk for new-onset diabetes, dyslipidemia and hypertension (49). 
However, surgery is not without complications. Abdominal pain is a common 
complication following gastric bypass, the prevalence shown to be between 22 and 
34% 3 to 5 years after surgery (50,51). Other side effects following bariatric surgery 
includes gallstones, kidney stones, hypoglycemia, diarrhea, dumping syndrome, 
fatigue, anemia, indigestion, and irritable bowel syndrome (51), at is it clear that careful 
considerations are needed when deciding on who should be recommended to undergo 
bariatric surgery. 
1.2 Adipose tissue 
1.2.1 Composition, functions and depots 
Adipose tissue is the main organ for storage of fat and regulation of energy balance and 
whole-body homeostasis. In response to high calorie levels, the adipose tissue stores 
free fatty acids (FFAs) as triglycerides (TGs), which happens through esterification of 
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the fatty acids. The FFAs can then be released from the tissue back into the circulation 
when energy levels are low (52), but may also occur in a situation of surplus energy 
intake when adipose tissue storage capacity is exceeded (53). The fatty acids are stored 
in lipid droplets within adipocytes in the adipose tissue. In addition to mature 
adipocytes, adipose tissue consists of a number of other cells types including progenitor 
cells, preadipocytes, immune cells, endothelial cells, fibroblasts, and stem cells, which 
together make up the stromal vascular fraction (SVF) (54). 
There are two main forms of adipocytes, white and brown, with a third and intermediate 
type of fat cell called beige adipocytes (54). Based on this, adipose tissue is broadly 
divided into two functionally distinct types, white (WAT) and brown (BAT) adipose 
tissue. Making up the majority of adipose tissue mass, WAT is the tissue that is mainly 
involved in storage and release of energy. BAT, on the other hand, utilizes stored 
energy to generate heat in a process called thermogenesis. This happens through the 
uncoupling protein-1 (UCP-1), which is a protein specific to BAT. Brown adipocytes 
contain a lot of mitochondria and UCP-1 localizes to the inner mitochondrial 
membrane. BAT is localized in smaller, more defined depots compared to WAT (55). 
Exposure of WAT to cold or adrenergic signaling may lead to the occurrence of UCP-
1+ brown-like adipocytes within the WAT. These cells, derived from white adipocytes, 
are called beige or brite adipocytes, have similar morpholical features to brown 
adipocytes, however, they have a different gene expression signature (54). 
In humans, white adipose tissue is localized in two main depots. The subcutaneous 
adipose tissue (SAT) is the fat tissue that is found under the skin and visceral adipose 
tissue (VAT) is localized in the abdominal region surrounding the inner organs (Figure 
1). A high amount of VAT is associated with metabolic disease, whereas SAT is 
sometimes thought to have beneficial effects on metabolism (54). 
In addition to its role as an organ for storage of excess energy, the adipose tissue is also 
an endocrine and immunological organ that secretes cytokines and hormones that 
regulate energy metabolism and maintain tissue homeostasis. The cytokines secreted 
by adipose tissue can be produced by the adipocytes themselves or from immune within 
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the tissue, such as macrophages and they can have both beneficial and harmful effects. 
In a state of obesity, adipose tissue can secret pro-inflammatory cytokines leading to a 
low-grade inflammatory environment in the tissue and that can affect insulin sensitivity 
systemically (56). Additionally, changes in adipose tissue mass in response to obesity 
can alter the endocrine and metabolic function of the tissue that further affects the 
physiology of the whole body (57). 
 
Figure 1. Main adipose tissue depots in humans 
Human adipose tissue localized in different depots. Subcutaneous adipose tissue (SAT) depots are 
found under the skin and include the abdominal, gluteal, and femoral. The visceral adipose tissue 
(VAT) surrounds the inner organs such as the intestines and stomach. Figure adapted with permission 
from (58).  
1.2.2 Adipocyte progenitor cells 
Adipocytes develop from adipocyte progenitor cells (APCs) that arise from stem cells 
(59). APCs, sometimes also referred to as preadipocytes, are a part of the stromal 
vascular fraction (SVF) of the adipose tissue and, when cultured in the presence of a 
cocktail of hormones, are able to differentiate into mature adipocytes. This cocktail 
usually includes insulin, glucocorticoid, phosphodiesterase inhibitors, and often a 
proliferator-activated receptor γ (PPARγ) agonist such as rosiglitazone (54). 
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APCs from SAT show a greater ability to proliferate and differentiate to mature 
adipocytes compared to progenitors from VAT (60,61). At the same time APCs from 
VAT are more susceptible to apoptosis than APCs from SAT (62). The progenitors 
seem to have distinct gene expression patterns depending on the depot from which they 
arise (63,64). APCs from VAT appear to have a lower capacity to differentiate in 
culture, and addition of stimulatory factors such as bone morphogenic protein (BMP)-
2 or 4 to the differentiation medium may improve the differentiation (63), indicating 
that the microenvironment is cruicial for proper adipocyte formation. 
White and brown adipocytes are derived from different precursor cells. In fact, brown 
adipocytes originate from the same or very similar precursors as muscle cells, namely 
the Pax7+/Myf55 stem cells. Development of brown adipocytes is further determined 
by the transcription factor PRDM16 (54,65). White adipocytes, on the other hand, are 
derived from Pax7-/Myf5- stem cells. These precursors also give rise to beige 
adipocytes, which differentiate when stimulated by cold or other inducers such as β3 
agonists (54). 
Several studies suggest that APCs may be identified based on their surface expression 
of stem cell markers such as CD34 and Sca-1 (59). Others define human adipocyte 
progenitors as Lin- CD29+ CD34+ Sca-1+ CD24+ cells. These cells may be sorted from 
the rest of the SVF based on their negativity for the markers CD31, CD45 and Ter119, 
which make up a linage-negative (Lin-) population. About half of the SVF cells were 
found to be Lin- CD29+ CD34+ Sca-1+ and these cells did not express the markers 
CD105 or CD117, which separated them from bone marrow-derived mesenchymal 
stem cells and hematopoietic stem cells. In mice, the expression of CD24 did not 
enhance the ability of the progenitors to differentiate into mature adipocytes, however, 
gene expression analysis pointed towards the fact that the CD24+ and CD24- 
preadipocytes were distinct populations (66). 
Human studies have identifed three subtypes of APCs (67). Progenitors that did not 
express CD34 were found to be beige-like. Adipocytes derived from APCs expressing 
high levels of CD34 had high levels of lipid turnover, whereas low expression of CD34 
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gave rise to adipocytes with low lipid turnover. The composition of the different 
progenitor populations differed depending on their depot of origin as well as the 
diabetes status of the individuals they were derived from. The abdominal SAT and 
VAT depots had lower numbers of progenitors compared to the gluteofemoral adipose 
tissue. However, VAT had more CD34hi APCs compared to SAT. Individuals with 
T2D had a lower proportion of CD34- cells and in concordance a higher proportion of 
CD34hi APCs (67). 
In a recent study, a stromal cell population expressing CD142 and that inhibited 
adipogenesis in a paracrine way was identified (68). In this study, they investigated 
Lin- CD29+ CD34+ Sca-1+ progenitor cells, which could be grouped in three clusters. 
One cluster of progenitors contained cells expressing stem cell markers, whereas 
another cluster of cells expressed genes involved in regulating early steps of adipocyte 
formation. The third group, making up around 10% of the APCs, contained the CD142-
expressing cells that were unable to differentiate into mature adipocytes and removal 
of this group of cells from the other progenitors enhanced the ability of the other cells 
to differentiate (68). Another study, however, found that CD142-expressing APCs were 
able to differentiate into adipocytes (69). Cells expressing dipeptidyl peptidase 4 
(DPP4), on the other hand, were highly proliferative cells but could not differentiate 
into mature adipocytes. Intracellular adhesion molecule -1 (ICAM-1) defined a 
committed progenitor population that expressed Ppparg and it was similar to the 
CD142+ progenitor population. However, the DDP4+ cells could differentiate into both 
ICAM+ and CD142+ progenitor cells that could further differentiate into adipocytes. 
The DDP4+ cells were dependent on the transforming growth factor-β (TGFβ) 
signaling in order to remain as progenitor cells. The number of DDP4-expressing 
progenitor cells were reduced in response to obesity and insulin resistance, leading to 





1.2.3 Adipose tissue secretion of adipokines and hormones 
Leptin 
The peptide hormone leptin is expressed by adipocytes and is important for regulating 
body weight. During fasting, leptin levels are low to promote food intake and reduce 
energy expenditure while in a fed state, leptin levels increase to prevent overfeeding. 
Plasma levels of leptin are correlated with adipose tissue mass and adipocyte size and 
thus obesity is associated with elevated circulating levels of leptin (70). Leptin is also 
expressed at higher levels in SAT compared to VAT and women generally have a 
higher production of leptin due to estrogen stimulation (70,71). Leptin is encoded by 
the obese (Ob) gene and mice that lack leptin become extremely obese (72). Humans 
with deficiencies in in either leptin or the leptin receptor experience a fast weight gain 
after birth leading to severe obesity as well as insulin resistance (73). Further, mutations 
in the leptin gene leads to monogenic forms of childhood obesity (74). 
Adiponectin 
In contrast to leptin, adiponectin is an adipokine that is associated with insulin 
sensitivity and whose circulating levels are negatively correlated with adiposity, with 
lower circulating adiponectin levels seen in obesity. Similar to leptin, adiponectin 
levels are also highest in SAT compared to VAT and in women compared to men (75–
77). Mice that lack adiponectin have high AT expression and plasma concentrations of 
tumor necrosis factor (TNF) and become insulin-resistant (78). The main function of 
adiponectin is to improve insulin sensitivity. Adiponectin also has anti-inflammatory 
properties promoting an anti-inflammatory macrophage phenotype, inhibiting 
differentiation of macrophages, and decreasing expression of TLR4. Adiponectin acts 
via receptors AdipoR1 and R2, increasing the activity of PPARα. This leads to 
increased fatty acid oxidation in the liver and skeletal muscle as well as increased 
glucose uptake by the liver and AT. At the same time, gluconeogenesis in the liver is 
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decreased. Activation of AdipoR1 and R2 by adiponectin also reduces levels of 
ceramide, a sphingolipid that is known to inhibit insulin signaling (79). 
1.2.4 Adipose tissue in obesity 
Adipose tissue dysfunction, hypertrophy and hyperplasia 
Obesity is associated with impaired AT function that is thought to be the link between 
obesity and metabolic and cardiovascular disease. The dysfunction of the adipose tissue 
leads to hypertrophy, ectopic fat accumulation, hypoxia, inflammation, autophagy, as 
well as stress and impaired mitochondrial function within the adipose tissue (80). In a 
state of obesity, the expansion of the adipose tissue in response to excess nutrients 
occurs through an increase in the number of adipocytes (hyperplasia) as well as an 
increase in the size of the adipocytes (hypertrophy) (81). Adipocyte numbers are 
thought to be determined during childhood and stays constant throughout adulthood, 
both in lean and obese and also after weight loss (82). Thus, hypertrophy is thought to 
be the main mechanism for adipose tissue expansion in adults. In mice, the 
subcutaneous AT has limited capacity for hyperplasia and hypertrophy occurs only 
after 2 months on HFD. Visceral adipose tissue, on the other hand, displays features of 
hyperplasia as well as hypertrophy (83,84). 
Lipotoxicity and hypoxia 
Adipocytes in SAT may eventually reach their storage capacity, in which fat starts to 
accumulate, first in VAT and then in other tissues such as the liver, skeletal muscle, 
and pancreas. This ectopic fat accumulation leads to lipotoxicity as the lipids are toxic 
to these non-adipose tissues. Further, ectopic fat can disturb the normal insulin 
signaling promoting insulin resistance (85). As the adipose tissue expands, the supply 
of oxygen may become limited leading to hypoxia. The hypoxic state of the tissue may 
cause both oxidative and endoplasmic reticulum (ER) stress, which further drives the 
AT dysfunction. Additionally, hypoxia may promote the secretion of pro-inflammatory 
cytokines (80). The transcription factor HIF-1α is activated in response to hypoxia and 
leads to reduced oxygen consumption and a shift in the fuel consumption of the cells 
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from oxidative phosphorylation to glycolysis (86). HIF-1α is also found to induce 
fibrosis as well as inducing polarization of pro-inflammatory macrophages leading to 
increased inflammation in the adipose tissue (87,88). 
Adipose tissue stress 
Both hypertrophy and ectopic fat accumulation may induce adipose tissue stress.  This 
stress may be in the form of oxidative stress, where enzymes involved in protection 
against such stress is found upregulated in adipose tissue of obese humans. Further, 
obesity is linked to ER stress, where the ER’s protein-folding machinery is overloaded 
leading to activation of a signaling pathway called the unfolded protein response (UPR) 
(89). This UPR can be activated in obesity due to hypoxia or high influx of nutrients to 
the cell and the ER (80). ER stress is implicated in the development of insulin resistance 
as it may affect insulin signaling by activation of the JNK pathway as well as 
phosphorylation of the insulin receptor substrate-1 (IRS-1) (90). 
ECM remodeling 
Expansion of adipose tissue in response to nutrient surplus requires remodeling of the 
extracellular matrix (ECM). As the main component of the ECM is collagen, this 
remodeling involves breakdown and synesis of collagen. Hypoxia may drive 
angiogenesis and ECM remodeling to drive expansion of the adipose tissue and thus 
reduce hypoxia. The remodeling is necessary for the early adipose tissue expansion, 
however, long-term obesity, on the other hand, is pathological and may lead to fibrosis 
(91). Further, pro-inflammatory signaling is required for appropriate expansion and 
remodeling (92). 
Autophagy 
Autophagy, the process where intracellular components are targeted for lysosomal 
degradation, is upregulated in obesity, especially in the visceral adipose tissue. Studies 
in mice has shown that autophagy is involved in regulation of fat mass and knockout 
of autophagy genes leads to lean, insulin-sensitive mice that do not develop obesity. 
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Thus, it is hypothesized that autophagy could be a protective mechanism against 
adipose tissue dysfunction (80). 
1.3 Insulin and insulin signaling 
Insulin is a peptide hormone that is produced by β-cells in the pancreas and secreted in 
response to elevated levels of blood glucose. Insulin promotes uptake of glucose in 
skeletal muscle and synthesis of glycogen for storage in muscle cells. Insulin also 
stimulates the liver to store glucose as glycogen, it stimulates de novo lipogenesis, 
while at the same time inhibiting gluconeogenesis (27). In the AT, insulin stimulates 
the enzyme lipoprotein lipase to increase fatty acid uptake from circulating lipoproteins 
(93). Further, insulin leads to storage of triglycerides in the AT and suppression of 
lipolysis though inhibition of hormone-sensitive lipase (27). (Figure 2) Insulin also 
promotes differentiation of preadipocytes into adipocytes and induces lipogenesis in 
mature adipocytes (93). 
Insulin signals through the insulin receptor on the surface of cells. This leads to 
recruitment and phosphorylation of tyrosine residues on the insulin receptor substrate 
promoting signaling through the phosphatidylinositol 3-kinase (PI3-kinase) and the 
protein kinase B (PKB)/Akt. PI3-kinase is an enzyme involved in phosphorylation of 
phosphoinositides and these phosphorylated inositols can activate the 
phosphoinositide-dependent kinase 1, which further activates the PKB/Akt through 
phosphorylation. Phosphoinositides also bind the plectrin homology domain of Akt and 
this causes recruitment of Akt/PKB to the plasma membrane. Activation of Akt/PKB 
induces translocation of the glucose transporter GLUT4 to the plasma membrane for 
uptake of glucose into cells (94). 
In a fasted state, secretion of insulin decreases leading to an increase in 
gluconeogenesis in the liver and breakdown of glycogen to glucose that can be released 
into the circulation. In the AT, lipolysis increases leading to release of glycerol and 
FFAs. Glycerol may enter the circulation and be transported to the liver where it can 
be used in gluconeogenesis (Figure 2) (27). 
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Figure 2. Overview of insulin action 
Left: In a fed state, intake of carbohydrates leads to increasing concentrations of plasma glucose. This 
stimulates production of insulin by the β-cells in the pancreas. Insulin exert different effects on 
metabolic tissues. In the skeletal muscles, it promotes uptake of glucose and synthesis of glycogen for 
storage. In the liver, insulin stimulates de novo lipogenesis and storage of glucose as glycogen, as well 
as inhibition of gluconeogenesis. In the AT, insulin stimulates fatty acid uptake from circulating 
lipoproteins and storage of triglycerides (TGs) while suppressing lipolysis.  
Right: In the fasted state, secretion of insulin is reduced, promoting gluconeogenesis in the liver and 
breakdown of glycogen to glucose for release into the circulation. In the AT, lipolysis is increased and 
this leads to release of glycerol and free fatty acids (FFAs). The glycerol can be used in 
gluconeogenesis by the liver. Figure adapted with permission from (27) 
1.4 The immune system and inflammation 
1.4.1 The immune system 
The immune system is a complex group of cells and molecules that are specialized in 
defending the body against infections (95).  The immune system is also involved in 
clearing of tumor cells and in maintaining tissue homeostasis (96). The immune system 
can respond to infectious agents through the innate or the adaptive immune system. 
The innate immune response is the first response against infections and occurs at the 
same strength each time. The adaptive or acquired response, on the other hand, improve 
and adapt with repeated encounter with the infectious substances. Phagocytic cells such 
as monocytes, macrophages, and neutrophils that produce different inflammatory 
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mediators as well as natural killer (NK) cells are all a part of the innate immunity. The 
adaptive immune response depends on specific T and B cells that proliferate in 
response to antigens (95,97). 
1.4.2 Leukocytes  
The cellular part of the immune system consists of leukocytes or white blood cells, 
which are derived from hematopoietic stem cell in the bone marrow that give rise to 
two types of progenitor cells namely the myeloid and the lymphoid progenitors. 
Leukocytes express the leukocyte common antigen also called CD45, and this surface 
receptor is therefore commonly used to identify leukocytes (98).  Macrophages, 
dendritic cells, granulocytes, and mast cells all originate from the myeloid progenitor 
(97). Macrophages are derived from monocytes, which are found in the circulation and 
mature into macrophages upon infiltration into tissues. Macrophages are phagocytotic 
cells and an important part of the innate immunity. Dendritic cells, involved in antigen-
presentation to lymphocytes, originate from immature dendritic cells that circulate in 
the blood and migrate to tissues. Mast cells also differentiate in tissue and activated 
mast cells influence vascular permeability. Granulocytes multiply in response to 
infections and travels to the sites of infection or inflammation. A type of granulocyte, 
the neutrophils, are also phagocytic and are one of the most important cell types in the 
innate immune system. Eosinophils are the main defense against infections with 
parasites (97). 
Lymphocytes, consisting of T cells, B cells, and innate lymphoid cells (ILCs), are 
derived from the lymphoid progenitors. T and B cells have antigen receptors that are 
able to bind many different antigen-binding sites (97). ILCs lack antigen-specific 
receptors and are divided into three groups. NK cells are cytotoxic ILCs and belong to 
the group 1 ILCs (ILC1s), which produce the cytokine IFN-γ. NK cells depend on IL-
15 for their development, whereas the other types of ILCs are dependent on IL-7, and 
hence they express the α chain of the IL-7 receptor. NK cell development is also 
dependent on the transcription factors T-bet and eomesodermin. ILC1s also require T-
bet, whereas ILC2s rely on GATA3 and the ILC3s on retinoid-related orphan receptor 
γt (RORγt) for their development. The ILCs are also distinguished by the cytokines 
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they produce. As mentioned, NK cells and ILC1s produce IFN-γ, ILC2s produce IL-1 
and IL-13, wheras ILC3s produce IL-17 and IL-22 (99,100).  
The NK cells are the most studied of the ILCs. They are large, granular lymphocytes 
that can recognize and kill abnormal cells such as virus-infected cells and tumor cells. 
NK cells are characterized by their expression of CD56 and a lack of expression of 
CD3 (101). NK cells express several activating receptors that can recognize molecules 
associated with conditions such as viral infections or cellular stress. Activating 
receptors expressed on NK cells include natural killer group 2, member D (NKG2D), 
natural cytotoxicity receptors (NCRs) NKp46/NCR1 and NKp30/NCR3, and DNAX 
accessory molecule 1 (DNAM1 or CD226). Inhibitory receptors include the killer cell 
immunoglobulin-like receptors (KIRs) and CD94-NKG2A. NK cells are targets of 
cytokines such as IFN-α and the interleukins (IL) 12, 15 and 18 promoting the NK cells 
to produce other cytokines and chemokines including IFNγ, TNF, and CCL4. NK cells 
are often divided based on their expression of the surface marker CD56. CD56bright NK 
cells are mainly cytokine-producing, whereas CD56dim NK cells are cytotoxic (102). 
The CD56dim NK cells express CD16, whereas expression of this receptor is absent on 
the CD56bright NK cells (101). NK cells may exert their cytotoxic functions through 
production of perforins and granzymes. Perforin is a membrane-disrupting protein 
while granzymes are proteases and together they can induce apoptosis of target cells 
(103). 
1.4.3 Circulating and tissue resident-immune cells 
As described above, many immune cell precursors circulate in the blood and 
differentiate as they enter different tissues. However, in recent years there is growing 
evidence for tissue-resident cells that exist in the tissue and that do not re-enter the 
circulation (102,104). Neutrophils and effector T cells are short-lived immune cells and 
they migrate to tissues in response to danger signals where they perform their functions 
and then die. Other immune cells such as ILCs, NK cells, DCs, macrophages, mast 
cells, and other types of lymphocytes may have to establish residency and adapt to the 
tissue environment (96). 
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Tissue-resident macrophages are mostly derived from yolk-sac macrophages or 
monocytes from the fetal liver and are established before birth. These tissue-resident 
macrophages are important for the normal tissue physiology and express tissue-specific 
residency-genes. They are highly adapted to the different tissues through unique 
transcriptional signatures, where genes encoding metabolic pathway proteins are 
especially important (96). 
Tissue-resident lymphoid cells are associated with expression of adhesion molecules 
and a lack of chemokine receptors. The blood and lymphoid organs contain 
sphingosine-1-phosphate and CCL19/21 that promote re-entering of lymphocytes to 
the circulation through their receptors sphingosine-1-phosphate receptor (S1PR1) and 
the chemokine receptor CCR7. S1PR1 and CCR7 are downregulated on tissue-resident 
cells (105). The surface markers CD69, CD49a, and CD103 are involved in keeping 
lymphocytes in tissues and can thus be used to identify tissue-resident cells. CD69 was 
thought to be an activation marker for both NK and T cells but is now recognized for 
its role in maintaining these cells in tissues though inhibition of the S1PR1. Human 
circulating NK cells lack CD69, whereas many subsets of tissue-NK cells express this 
marker. Different types of tissues contain different amounts of tissue-resident NK cells. 
CD103 and CD49a retain tissue-resident cells in the tissue through their binding to E-
cadherin and collagen, respectively. Their expression is controlled by transforming 
growth factor β (TGFβ) and they are found to be expressed on tissue-resident CD69+ 
T cells and on some subsets of tissue-resident NK cells (102). 
1.4.4 The inflammatory response 
Inflammation is a protective mechanism the immune system generates that can be 
triggered by both infectious and non-infectious agents. Infectious agents include 
bacteria, virus, and other microorganisms. Non-infectious agents might be either 
physical in the form of burns, trauma, frostbites etc., be in the form of chemical agents 
such as toxins, glucose, fatty acids, alcohol, or chemical irritants or biological in the 
form of damaged cells. The inflammatory response induces a signaling cascade to 
initiate a healing process (106). Inflammation is typically characterized by swelling, 
redness, heat, pain, and loss of tissue function. These symptoms are caused by an 
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increase in the permeability of the vascular endothelium leading to a leakage of 
components from the serum and recruitment of cytokine-producing immune cells 
leading to induction of the inflammation (107). 
All inflammatory responses happen through the same mechanism involving four main 
processes. Firstly, the inflammatory response is triggered by infectious or non-
infectious agents through pathogen-associated molecular patterns (PAMPs) or danger-
associated molecular patterns (DAMPs) respectively. This leads to activation of 
pattern-recognition receptors (PRRs) that may be expressed on both immune and non-
immune cells. Types of PRRs include the well-studied toll-like receptors (TLRs) as 
well as C-type lectin receptors, retinoic acid-inducible gene (RIG)-I-like receptors, and 
NOD-like receptors. Activation of PRRs triggers inflammatory signaling pathways that 
upregulate transcription of inflammatory mediators such as ILs and TNF. These 
mediators bind to their respective receptors activating important intracellular signaling 
pathways. Important pathways include the mitogen-activated protein kinase (MAPK), 
the nuclear factor kappa B (NF-κB), and the Janus kinase (JAK)-signal transducer and 
activator of transcription (STAT) pathways. These pathways triggers production of 
inflammatory markers such as cytokines and chemokines leading to recruitment of 
inflammatory immune cells (106). 
1.5 Adipose tissue immunology and inflammation 
Adipose tissue homeostasis involves a number of immune cells such as macrophages, 
eosinophils, ILC2s, invariant NKT cells (iNKT) cells, NK cells, mucosal-associated 
invariant T (MAIT) cells, γδ T cells, and regulatory T cells (Treg cells). These cells 
maintain an anti-inflammatory environment and prevent activation of pro-
inflammatory macrophages. Several types of immune cells have also been implicated 
in AT in relation to obesity. The AT immune cells in lean and obese AT is summarized 
in Figure 3 (96). 
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1.5.1 Adipose tissue resident macrophages support adipose 
tissue homeostasis 
Resident ATMs stimulate increased vascularization of the tissue thereby reducing 
hypoxia (96). Further, these ATMs remove apoptotic cells through efferocytosis. Lean 
AT contains mostly anti-inflammatory macrophages that have increased mitochondrial 
function and increased β-oxidation linked to improved lipid catabolism. The increased 
β-oxidation is necessary for clearing of the excess lipids that the macrophages obtain 
from the dead cells during efferocytosis (108). The macrophages are also involved in 
tissue repair, which is promoted by the apoptotic cells as well as the cytokines IL-4 and 
IL-13 that induce expression of tissue-repair genes (109). The IL-4-production in lean 
AT is mostly derived from eosinophils, which may produce up to 90% of the IL-4 
(110). In mice, IL-4 and alternatively activated macrophages are also found to promote 
thermogenic gene expression, fatty acid mobilization, and energy-expenditure (111). 
Moreover, IL-4 and macrophage colony stimulating factor (M-CSF) is known to 
stimulate glucose metabolism during activation of M2 macrophages and glucose is 
found to be essential for alternative activation of macrophages. IL-4 and M-CSF signal 
through the mammalian target of rapamycin complex 2 (mTORC2) and interferon 
regulatory factor 4 (IRF4) to affect the glucose metabolism and this process is essential 
for activation of M2 macrophages (112). 
Maturation of alternatively activated macrophages is dependent on PPARγ, which is 
also implicated in the macrophages’ ability to maintain insulin sensitivity in mice 
(113). Resident ATMs may regulate tissue homeostasis through production of IL-10 
and catecholamines. IL-10 is thought to block infiltration of macrophages and gene 
expression of genes encoding pro-inflammatory cytokines while the catecholamines 
may induce lipolysis in white adipocytes and expression of thermogenic genes in 
brown adipocytes (111,114). However, others have found that IL-10 does not reduce 
inflammation and insulin resistance and that it may suppress transcription of 
thermogenic genes, whereas IL-4 does not stimulate production of catecholamines by 
alternatively activated macrophages (115–117). Thus, the role of anti-inflammatory 
macrophages and the cytokines they produce, especially in humans, is not fully 
understood. 
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1.5.2 Adipose tissue T cell populations supports tissue 
homeostasis and have anti-inflammatory functions 
Treg cells are a group of CD4+ T cells that express the transcription factor Foxp3. They 
have functions in autoimmune and autoinflammatory disorders, cancer, allergy, and 
acute and chronic infections. Further, Tregs are known to be involved in metabolic 
inflammation and tissue repair (118). A unique population of AT Tregs was identified 
in lean, but not obese mice. The percentage of Treg was also higher in VAT compared 
to SAT. VAT Tregs expressed high levels of IL-10, which was found to affect adipocytes 
by inhibiting TNF-induced pro-inflammatory gene expression and reversing the effect 
of TNF to inhibit glucose uptake. Thus, IL-10 is thought to reduce insulin resistance 
(119). Further, Tregs found in VAT express elevated levels of genes encoding molecules 
important for lipid metabolism. Accumulation of Tregs in VAT as well as their 
phenotype and function are regulated by PPARγ (120). 
Tissue-resident γδ T cells are also abundant in AT and are found to regulate the 
expansion of Tregs. These γδ T cells produce IL-17A that induce IL-33 production by 
AT stromal cells (121). γδ T cells are also found to be expanded in AT after a short-
term ketogenic diet in mice. These γδ T cells were also tissue-resident, thought to be 
involved in adipose tissue remodeling and homeostasis and mice lacking these γδ T 
cells had impaired glucose homeostasis (122). 
Tissue-resident iNKT cells in VAT is shown to produce IL-2 and IL-10, which 
controlled AT Treg numbers and proliferation. They also promote alternatively 
activation of macrophages through their production of IL-4 (123). Further, AT iNKT 
cells are associated with decreased body fat, triglyceride and leptin levels as well as 
improved insulin sensitivity which is mediated by their production of anti-
inflammatory cytokines such as IL-4 and IL-10. Mice lacking iNKT cells gain more 
weight, have larger adipocytes, more hepatic fat, elevated fasting blood glucose levels 
and higher levels of insulin resistance compared to mice with iNKT cells (124). 
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Figure 3. Lean and obese AT 
In lean AT, Tregs, iNKT cells, and eosinophils promote anti-inflammatory signaling through 
production of IL-4, IL-10, and IL-13, stimulating the anti-inflammatory M2-like phenotype of the 
adipose tissue macrophages (ATMs). The immune cells maintain the tissue homeostasis and are 
involved in remodeling of the tissue. In an obese state, adipocytes are bigger and there is an 
infiltration of pro-inflammatory M1-like macrophages driven by the chemokine MCP-1. Further, 
M2-like macrophages polarize to M1-like macrophages. This leads to increased production of pro-
inflammatory cytokines such as TNF and IL-6, which contribute to the development of insulin 
resistance. NK cells contribute to macrophage polarization trough production of TNF and IFN-γ. NK 
cells also has reduced capacity to kill M2-like macrophages, which can then polarize to M1-like 
macrophages. Figure adapted with permission from (109). 
1.6 Obese adipose tissue immunology 
The first reports suggesting that adipose tissue inflammation was linked to obesity and 
T2D came from studies revealing that expression of TNF is elevated in the AT of obese 
mice (125). Further, TNF can block insulin signaling, and mice that lack either TNF or 
its receptors have improved insulin sensitivity and experience increased insulin-
stimulated glucose uptake (125,126). Many genes related to inflammation and 
macrophages are upregulated in adipose tissue of obese mice and in obesity there is an 
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accumulation of macrophages in the adipose tissue (127,128). Removing M1-like 
macrophages in mice is shown to reduce inflammation and improve insulin sensitivity 
in adipocytes (129). In addition to TNF, cytokines, and chemokines such as IL-6, IL-
1β, monocyte chemoattractant protein -1 (MCP-1) also called C-C chemokine ligand 2 
(CCL2) and macrophage inflammatory protein (MIP) are all secreted by ATMs. 
Transcriptionally, the production of these cytokines is controlled by two signaling 
pathways, namely the c-JUN N-terminal kinase (JNK)-activator protein 1 (AP-1) and 
Iκ B kinase β (IκK)-nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB). 
These signaling pathways can be induced by ER and oxidative stress, saturated fatty 
acids (SFAs), and pro-inflammatory cytokines (130). Obesity associated activation of 
these two inflammatory signaling pathways can be achieved in several ways. Cytokines 
may activate their cell surface receptors or the signaling may be induced through 
activation of PPRs such as NODs or TLRs. The PPRs respond to PAMPs such as LPS 
or bacterial DNA or DAMPs, which includes SFAs. TLR4 especially has been 
implicated in promotion of SFA-induced macrophage inflammation (131). PAMPs and 
DAMPs associated with obesity are also associated with activation of the nucleotide-
binding domain and leucine-rich-repeat-containing protein NLRP3 inflammasome  
(132). Reactive oxygen species, hypoxia, ER stress, and lipotoxicity are also shown to 
induce inflammatory signaling pathways (133). 
1.6.1 Macrophages 
During development of obesity, macrophages accumulate in the AT making it the most 
abundant type of immune cell in the obese AT. Adipose tissue macrophages (ATMs) 
make up around 10 – 15 % of the AT immune cells in lean mice and increase to 40 – 
60 % in AT of obese mice (127,128).  Most of the macrophage populations that emerge 
during obesity is thought to be derived from circulating monocytes and not from tissue-
resident macrophages (134). The chemokine MCP-1/CCL2 is thought to be the main 
driver of macrophage infiltration into the AT during development of obesity (135–
137). In mice, its expression is upregulated in obesity (135), overexpression leads to 
recruitment of macrophages and development of insulin resistance (137) while deletion 
of CCL2 or its receptor CCR2 prevents infiltration of macrophages and protects against 
insulin resistance (136). 
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Several studies also find that local proliferation of ATMs contribute to the increase in 
the number of ATMs in obesity, in both mice and humans. This proliferation might be 
driven by CCL2 (138), however, others find that this cytokine was not increased along 
with increased proliferation of macrophages (139). It has also been suggested that 
macrophages localized in crown-like structures (CLS) around necrotic adipocytes, 
proliferate and become more M2-like in their phenotype and this has been found in 
both mice and human AT (140). CD68 is considered the classical macrophage marker 
that is found to correlate with BMI and adipocyte size (127). 
It is thought that most of the macrophages in obese AT localize in CLS. These CLS 
have been found in both mice and humans and some studies find that they mostly 
consist of M1-like or pro-inflammatory macrophages (141). The pro-inflammatory 
M1-like macrophages produce inflammatory cytokines such as IL-6, IL-1β, inducible 
nitric oxide synthase (iNOS), and TNF. Obesity reduces the expression of genes 
characteristic of M2-like macrophages and induces expression of genes encoding TNF 
and iNOS, which are markers of M1-like macrophages suggesting that obesity induces 
a phenotypic switch leading to polarization of macrophages from an anti-inflammatory 
M2 to a pro-inflammatory M1-like phenotype (142). M1-like macrophages are also 
found to be induced by lipopolysaccharide (LPS) and INFγ (143). 
Human M1-like macrophages can be identified by their expression of the surface 
marker CD11c, which is not expressed on M2-like macrophages (141). M1-like 
macrophages also express CCR2, CD64, and CD206. Further expression of TLR4, 
CD40, and HLA-DR might also define M1-like macrophages. Human M2-like 
macrophages are defined as expressing CD206 and CD204 (144). Some also suggest 
they express CD163 (145), although this has been debated and CD163 has also been 
reported to be expressed on M1-like macrophages (144). 
M1-like ATMs were also found to express the surface marker CD11c in mice. One 
study found that the CD11c+ ATMs did not change in numbers when the mice became 
insulin resistant after HFD-feeding. However, the macrophages exhibited a changed 
phenotype where markers of inflammatory pathways were no longer present and 
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instead markers of apoptosis and necrosis were increased. This suggest that M1-like 
ATMs may be highly plastic cells that are able to change their phenotype with a 
changing microenvironment (146). 
Triggering receptor expressed on myeloid cells (TREM)-1 is found to be increased in 
AT, liver, and blood of individuals with obesity, both those with and those without 
diabetes. On the other hand, levels of TREM2 were decreased, both on a transcriptional 
level and also its protein expression in liver, SAT, and VAT (147). Some of these 
studies also find that TREM1 expression is higher in subjects with obesity and diabetes 
compared to subject with obesity, but without diabetes (147,148). Human ATMs may 
in some settings display a mix between a pro- and anti-inflammatory phenotype, where 
the ATMs express typical M2 surface markers, but at the same time are able to secrete 
high amounts of pro-inflammatory mediators such as TNF, IL-6, IL-1β, and MCP-1 
(145). 
1.6.2 Different types of ATMs detected in AT 
It is thought that the M1/M2 classification is a simplification of the macrophage 
phenotypes. Accordingly, several types of ATMs have been identified and 
characterized in AT. Both monocytes and macrophages undergo remodeling during 
development of obesity. A recent publication showed that two macrophage populations 
in AT of mice showed a gradual expression of genes. One of these was the gene 
encoding the tetraspanin Cd9, a marker that has been described expressed on human 
ATMs (134,149). A population of CD9+ CD63+ macrophages seemed to be present 
during obesity and these macrophages were found in CLS around adipocytes (134). 
A recent scRNA-seq of human adipose tissue cells revealed 5 different clusters of 
macrophages. One of the clusters had a higher expression of CD9 than the other 
subtypes of ATMs. This macrophage population was also enriched for genes connected 
to lipid metabolism. Further, CD9 expression was associated with BMI. Another 
subgroup of macrophages had a similar expression signature compared to this CD9-
expressing population, however, this group also had increased expression of 
inflammatory genes. A cluster expressing M2-related genes was also identified, 
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whereas one of the clusters could not be further identified. One of the macrophage 
clusters turned out to be dendritic cells, while the last group was identified as CD16- 
monocytes (150). Hence, there is evidence that several subpopulations of ATMs exist 
in human AT. 
There are still a lot of details about ATMs that are yet to be elucidated. More studies 
analyzing ATMs on a single-cell level will lead to increased insight into the different 
subtypes that might exist in the AT. Here some of the suggested macrophage subtypes 
that are shown be present in AT are presented (Figure 4).  
Lipid-associated macrophages (LAMs) 
A subset of ATMs express genes encoding molecules related to lipid metabolism and 
phagocytosis and thus they are referred to as lipid-associated macrophages (LAMs). 
This is a unique population of ATMs, found in both mice and humans, that express the 
marker Trem2, which is a marker that is not expressed on any other type of immune 
cell present in the AT (134). Trem2 is co-expressed with CD9 on the LAMs. LAMs in 
adipose tissue resembles disease-associated microglia and hepatic Trem2+ immune 
cells in their gene expression signature, suggesting that Trem2 may define a specific 
type of macrophage across different tissues. LAMs can be identified by flow cytometry 
as CD9+ CD63+ macrophages and these cells contain intracellular lipids, further 
underlining their roles in lipid metabolism. In the absence of Trem2, mice did not 
accumulate LAMs in their AT and thus LAMs could not take up and store lipids in an 
obese state. Lack of Trem2 also leads to adipocyte hypertrophy in mice on HFD as well 
as increased fat accumulation, glucose intolerance, high serum insulin levels, and 
dyslipidemia. This suggests that Trem2 may be important for AT function and 
metabolic health (134). Furthermore, mice lacking Trem2 have lower circulating levels 
of MCP-1 and reduced infiltration of AT macrophages that were not able to form CLSs 
and clear dead adipocytes. Additionally, Trem2-deficient mice had severe hepatic 
steatosis following HFD compared to WT mice (151) TREM2-expressing LAMs have 
also been identified in human AT, expressing many of the same genes as mice LAMs. 
Further, LAMs were only found in AT of obese individuals and their proportion was 
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positively correlated with BMI. TREM2 was also only expressed on LAMs and not on 
any other AT immune cell type (134). 
 
Figure 4. Subtypes of adipose tissue macrophages 
Macrophages are derived from monocytes that, depending on the stimuli, can differentiate into 
different subtypes of macrophages. M1-like macrophages (M1) can develop after stimuli with 
interferon (IFN)-γ or tumor necrosis factor (TNF). These macrophages express the surface proteins 
CD11c, CD206, and CCR2. M2-like macrophages (M2) originate from stimulation with IL-4 and IL-
13, and express surface proteins CD206, CD204, and CD163. The metabolically activated 
macrophages arise after stimuli with glucose, insulin or free fatty acids. Lipids can also stimulate the 
development of Mox macrophages. MMes typically express CD36, ABCA1, and PLIN2, while the 
Mox macrophages express heme oxygenase-1 (HO-1), sulforedoxin-1 (Srnx-1), and thioredoxin-1 
reductase (Txnrd-1). M1-like macrophages, MMes and Mox macrophages all develop in response to 
obesity. This is also the case for the lipid-associated macrophages (LAMs), which are characterized by 
expression of CD9, CD63, and TREM2. Figure adapted with permission from (144). 
 
Metabolically activated macrophages (MMe’s) 
Another type of macrophage, the metabolically activated macrophages (MMe) are 
found in AT of both mice and humans. These macrophages are activated by metabolic 
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stimuli such as high levels of insulin, glucose and palmitate. They do not express the 
classical M1 surface markers such as CD274, CD319, and CD40, but rather express 
distinct cell surface proteins compared to M1 macrophages. MMe macrophages 
express markers involved in lipid metabolism including ABCA1, CD36, and PLIN2. 
These markers are generally associated with M2 macrophages, however, M2 markers 
such as CD206 or CD163 are not expressed on the MMes. The surface markers induced 
in MMes are found to be regulated by PPARγ through its binding to the promoters for 
PLIN2, CD36, and ABCA1 in both mice and humans. Treating macrophages with 
medium conditioned by adipose tissue induced expression of ABCA1, CD36, IL1β, and 
TNF (152). 
MMe macrophages have both beneficial and detrimental functions. These macrophages 
are pro-inflammatory and able to secrete cytokines (detrimental function), but they are 
also involved in the clearance of dead adipocytes through lysosomal exocytosis 
(beneficial function), evident by their expression of cells surface proteins lysosomal-
associated membrane protein (LAMP)1 and LAMP2. Their inflammatory cytokine 
production is regulated by TLR2, TLR4, NOX2, and MYD88 and macrophages lacking 
Nox2, Tlr2, and Myd88 have impaired lysosomal exocytosis. The MMe phenotype can 
be detected in mice after eight weeks on an HFD, where the macrophages produce 
cytokines and expresse genes involved in lipid metabolism. However, hypoxia, 
apoptosis, CLS, or ectopic fat storage were not identified at this time. After 16 weeks 
on HFD, evidence of hypoxia and apoptotic adipocytes was detected in the AT. Further, 
lipid storage was seen in the liver and the MMes showed a more distinct MMe 
phenotype. This suggests that the clearance of dead adipocytes may only be needed 
after long-term HFD (153). 
Hill and colleagues identified several unique ATM populations in mice, defined by 
surface markers CD9 and Ly6c (149). CD11b+ LY6c+ cells were assumed to be 
monocyte-derived macrophages, whereas CD11b+ LyC6- macrophages also expressed 
macrophage markers F4/80 and CD64. Both of these cell types were increased 
following HFD. The LyC6- cells consisted of two different populations, one of these 
expressed high levels of Cd9. Consistent with findings by others (152,154), these CD9+ 
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cells also expressed genes associated with lipid metabolism, such as Plin2 and Lpl and 
genes related to intracellular vesicle function such as Lamp2 and Cd63. The CD9+ 
ATMs were also found to accumulate in the AT following HFD, whereas CD9- ATMs 
did not. Further, the CD9+ ATMs were localized in CLSs, contained intracellular lipids 
and secreted exosomes. Both the CD9+ and the LyC6+ ATMs were distinct from M1 or 
M2 macrophages in their transcriptome, however, the CD9+ ATMs expressed 
proinflammatory genes as well as genes associated with lysosomal pathways. The 
LyC6+ ATMs, on the other hand, expressed genes involved in vascular development 
and organization. CD9+ ATMs were also found in human AT, and these cells also 
contained intracellular lipids and localized in CLSs. Moreover, BMI was positively 
correlated with the amount of CD9+ ATMs in VAT (149). 
Mox macrophages 
A new macrophage phenotype was identified in atherosclerotic lesions that was 
different from M1 and M2 macrophages. These macrophages, called Mox 
macrophages can develop from M1 or M2 macrophages that undergo a phenotypic 
switching when treated with oxidized phospholipids. Mox macrophages have a 
different gene expression profile compared to M1 and M2 and their capacity for 
phagocytosis and migration is decreased. These macrophages are thought to develop 
in response to oxidative tissue damage. The Mox macrophages were associated with 
redox regulation and antioxidant activity and their phenotype was regulated by the 
transcription factor Nrf2 (155). 
A cell population with a phenotype resembling the Mox macrophages was also 
identified in murine AT. Firstly, lean mice had an ATM population that was CX3CR1-
/F4/80lo while AT from obese mice showed an accumulation of CX3CR1+/F4/80hi cells. 
The resident F4/80lo population in lean mice was associated with the Mox markers 
Txnrd1 and HO1. These markers are redox homeostatic enzymes and their expression 
is driven by Nrf2. The F4/80hi population, on the other hand, expressed CD11c and 
CD206, in concordance with the inflammatory macrophages seen in human obese AT. 
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This population was also present in lean AT and increased during HFD while the Mox 
macrophage numbers were unchanged (156). 
1.6.3 NK cells and ILCs 
Obesity is associated with increased levels of AT NK cells, which is mostly seen in 
VAT and not in SAT (157–159). Ablation of NK cells decrease macrophage infiltration 
into VAT but not SAT and improve insulin resistance (160). Obesity may drive 
proliferation of and cytokine production by ILCs, which may further induce 
polarization of ATMs leading to development of insulin resistance. In mice, obesity is 
found to promote expression of stress ligands on adipocytes that can bind the activating 
NK cell receptor NCR1 (Figure 5). The human equivalent, NKp46 was also found to 
be expressed in human VAT, but not SAT (158). HDF leads to accumulation of IFN-
γ- producing NK cells in the adipose tissue (158,161). IFN-γ is known to promote 
macrophage polarization during infections (162) and depletion of IFN-γ reduce insulin 
resistance in obese mice (163). The increase in NK cells during HFD also increased 
polarization of macrophages into an M1-like phenotype leading to insulin resistance. 
Depletion of NK cells, the NCR1 or IFN-γ, on the other hand, led to decreased numbers 
of both total and M1-like macrophages as well as improvements in AT inflammation 
and insulin sensitivity without affecting the body weight (157,158). Another study 
found that the AT NK cells in obese mice produced higher amounts of TNF than AT 
NK cells from lean mice. They also found that IL-15, produced by both sorted ATMs 
and epididymal fat, but not subcutaneous fat, drove proliferation and activation of AT 
NK cells (157). This suggests that NK cells, through their production of INF-γ or TNF, 
may play a role in macrophage polarization and development of obesity-induced 
insulin resistance, however human studies are needed. 
A subset of group 1 innate lymphoid cells (ILC1s) is also identified in murine adipose 
tissue, which contribute to metabolic disease. These ILC1s are phenotypically and 
functionally different from AT NK cells, they are dependent on transcription factors T-
bet and Nfil3 and they are tissue-resident. Diet-induced obesity led to an increase in 
ILC1 density, an increase that was small and transient in VAT and large and sustained 
in SAT, suggesting that SAT is the dominant depot for ILC1 accumulation during 
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obesity (161). Obesity also led to production of the cytokine IL-12, which induced 
proliferation and accumulation of ILC1s. This was dependent on signaling through the 
IL-12 receptor and STAT4. Additionally, the ILC1s were found to produce IFN-γ, 
leading to polarization of M1-like macrophages and development of insulin resistance 
(161). 
Another type of ILC, called adipose type 1 innate lymphoid cells (AT1-ILCs) work by 
targeted cytotoxicity towards ATMs. These AT1-ILCs were found to kill the M2-like 
macrophages, which were assumed to be a way of removing M2-like ATMs that have 
fulfilled their homeostatic role and prevent them from develop into pro-inflammatory 
M1-like macrophages (164). The numbers of the AT1-ILCs were found to increase 
within the first days of putting mice on a HFD, however, as obesity was sustained, the 
levels of AT1-ILCs were found to decrease, both in humans and mice. In obesity, these 
AT1-ILCs also lost their ability to kill the M2-like macrophages and this led to an 
increase in ATMs and a shift towards more M1-like macrophages. ATMs were also 
found to express the NKG2D ligand Rae-1, and the expression was increased after HFD 
(164). NK cells and macrophages are known to interact with each other through 
NKG2D-Rae1 in infections or inflammation induced by LPS (165). It is unclear if 
ILC1s exsist in humans or if they rather correspond to CD56bright NK cells (166). 
Several studies point towards altered NK cell phenotype and function in obesity (167–
169). Obesity is associated with a shift from cytotoxic CD56dim to cytokine-producing 
CD56bright NK cells, which might explain the increased secretion of cytokines by AT 
NK cells associated with obesity. AT NK cells from individuals with obesity also 
showed decreased expression of NKp30 and NKp44 and unchanged levels of NKG2D 
(170). AT NK cells also possess an activated phenotype in human obesity, with 
increased frequency of CD56bright NK cells and a reduction in CD56dim NK cells within 
the total NK cell population in SAT and VAT compared to PBMC from individuals 
with obesity.  Further, the frequencies of NK cells expressing CD158, NKG2D, NKp46 
or CD27 as well as CD16dim NK cells are increased while CD16bright NK cell levels 
were decreased in VAT compared to PBMC(171). Development of T2D is associated 
with a lower frequency of inhibitory NK cells and a higher frequency of activated NK 
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cells seen by higher levels of NKG2D+ NK cells and lower levels of NKG2A+ and 
KIR2D3+ NK cells in the T2D patients compared to controls (172). In mice, obesity is 
also associated with a subpopulation of NK cells expressing IL6Ra, which express the 
myeloid linage gene colony-stimulating factor 1 receptor (Csf1r). Depletion of NK 
cells expressing Csf1r prevents obesity and insulin resistance. Further, inactivation of 
IL6Ra or Stat3 in the NK cells limits the development of these Csf1r-expressing NK 
cells and this also protected against obesity and associated inflammation and insulin 
resistance (173). 
Alterations in NK cell numbers are also seen in obesity. Childhood obesity is associated 
with reductions in peripheral NK cell frequency compared to normal weight children. 
Obese children had NK cells that were activated, metabolically stressed, and had 
reduced ability to respond to stimulus that lead to a loss of function (174).  Several 
studies also show that the frequency of circulating NK cells is decreased in obesity 
(167,169,175). Studies in mice show that NK numbers are decreased or not changed in 
obesity (176,177), whereas one study found NK cell frequencies to be dependent on 
leptin as NK cell levels increased following HFD, however not in leptin-deficient 
(ob/ob) mice (178). 
NK cells from individuals with obesity expressed elevated levels of activation markers 
CD69 and granzyme B and reduced levels of CD16. Further, reduced expression of the 
natural cytotoxicity receptor NKp46 and NKG2A/CD94 complex is seen on these NK 
cells. The NK cells also display a loss of function measured by their decreased ability 
for degranulation and production of MIP-1β and IFN-γ in line with increasing BMI 
(179). This is in contrast to findings by others suggesting an increase in the production 
of IFN- γ by NK cells in obese AT. Different obesity-related adipokines may affect NK 
cells. Leptin may influence proliferation and migration of NK cells, whereas 
adiponectin increases expression of the degranulation marker CD107a and the 
cytotoxicity of the NK cells. Both the leptin and adiponectin receptors are thought to 
be expressed on NK cells (180). 
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Altered NK cell function in relation to obesity is also suggested to be one of the links 
between obesity and cancer. Obesity stimulates metabolic reprogramming of NK cells, 
where PPAR-signaling cause accumulation of lipids in the NK cells, evident by 
obesity-driven upregulation of genes related to lipid metabolism, lipid-droplet 
formation and lipases as well as genes associated with lipid and glycerol uptake. 
Further, obesity also lead to downregulation of NK cell-mediated cytotoxicity. NK 
cells from obese individuals produce less IFN-γ and are able to kill tumor cells to the 
same extent as NK cells from lean individuals. Further, the NK cells experience a loss 
of perforin and granzyme B and this loss of function is thought to be due to lipid uptake 
by the NK cells in response to increasing concentrations of FFA in obesity. The 
mTORC1 pathway, which is essential for NK cell function, is also found to be impaired 
in obesity. Thus, obesity and the associated lipid-rich environment may impair the 
ability of the NK cells to perform their immunosurveillance function and their 
cytotoxicity against tumor cells seems to also be reduced in obesity (169). 
1.7 Inflammation-mediated insulin resistance 
M1-like macrophages may impair insulin signaling through secretion of cytokines such 
as TNF, IL-6, and IL-1β (181). These cytokines can induce insulin signaling through 
both transcriptional and posttranscriptional mechanisms. Some of these mechanisms 
involve the two serine kinases IKKβ and JNK (133,182) that can reduce insulin 
signaling by inhibitory phosphorylation of the insulin receptor (IR) and the insulin 
receptor substrate (IRS) (183,184). Further, activation of JNK activates AP-1 while 
IKKβ promotes translocation of NK-κB to the nucleus. These transcription factors 
stimulate expression of inflammatory genes such as those encoding TNF and IL-6, 
further promoting insulin resistance (185). Posttranscriptional mechanisms include 
those affecting mRNA or microRNA (miRNA). Stabilization of mRNA encoding 
inflammatory cytokines, which may happen through JNK signaling can also promote 
inflammation (186). TLR4-signaling may impair expression of the miRNA miR-223, 
promoting production of IL-6 and IL-1β (187). 
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TNF itself can increase lipolysis, leading to a release of FFAs that are able to bind and 
activate TLR4 and thus affect insulin signaling through IKKβ (133). TNF can also 
impair insulin signaling by decreasing the expression of GLUT4 or PPARγ (188,189). 
Obesity-induced inflammatory signaling also induce the synthesis of ceramides, and 
this group of bioactive sphingolipids may also assert negative effects on insulin 
signaling. Ceramides are found to block the recruitment of PKB/Akt to the plasma 
membrane and instead recruit and activate an atypical protein kinase C, the protein 
kinase C ζ. This leads to phosphorylation of the PH domain of Akt thereby decreasing 
the affinity of the PH domain for phosphoinositides and further inhibition of insulin-
stimulated Akt-activation (190,191). Inflammatory mediators can also induce de novo 
lipogenesis in the liver leading to elevated levels of serum lipids (192).  Obesity is also 
associated with elevated levels of fatty acid binding protein 4 (FABP4), a protein that 
can be produced by macrophages, however, is mainly produced by adipocytes. In 
macrophages FABP4 promotes induction of the IKK-NF-κB and the JNK signaling 
pathways, while in adipocytes this protein activates hormone-sensitive lipase to 
regulate lipolysis (193) (Figure 5). 
There is still a lot to be known about immune cell composition in blood, liver and AT 
in human obesity and how different immune cell population associates with degree of 
NAFLD or insulin resistance. Further, markers identifying progenitor cells present in 




Figure 5. NK cells, ATMs and insulin resistance  
In an obese state, NK cells secrete cytokines that drive polarization of M1-like macrophages. NK cells 
may also lose their ability to kill M2-macrophages. This leads to an increase in the numbers of M1-
like ATMs. Pro-inflammatory cytokine production by ATMs drive development of insulin resistance 
though several mechanisms. IkBkinase-b (IKKb) and JUN N-terminal kinase (JNK) may 
phosphorylate insulin receptor (IR) and insulin receptor substrate (IRS) at inhibitory sites, which block 
insulin signaling. Further, activated IKKb leads to translocation of NF-kB to the nucleus and JNK 
activation can activate AP-1. The transcription factors NF-kB and AP-1 promote expression of 
inflammatory genes, such as TNF and IL-6, which can further induce insulin resistance. ATMs also 
produce TNF, which can promote lipolysis leading to release of FFAs that can bind TLR4 and affect 
insulin signaling. Phosphorylation of IRS can also inhibit signaling through PI3-kinase and the protein 
kinase B (PKB)/Akt pathway. In the end, this leads to reduced translocation of the glucose transporter 







The aims of this thesis were to characterize both circulating and tissue immune cells in 
individuals with obesity and to explore their associations with degree of NAFLD 
progression or insulin resistance. Further, the aim was to explore the heterogeneity of 
adipose tissue cells 
Specific aims include: 
1) Perform an in-depth phenotypic and functional analysis of circulating NK cells 
as well as characterize NK cells in liver and AT in patients with NAFLD and 
NASH.  
2) Characterize ATMs phenotypically and measure circulating inflammatory 
factors in obese individuals with varying degrees of insulin resistance.  
3) Explore the heterogeneity of adipose tissue myeloid cells and preadipocytes by 
performing a surface proteome screening and integrating this with analysis of 




3. Comments on methods 
3.1 Patient samples (Papers I-III) 
The human studies were all approved by the local ethics committee and the subjects 
gave written informed consent. The studies in paper I were approved by the regional 
ethics committee in Stockholm (Dnr’s 2010/678-31/3, 2006/971-31/1, 2006/229-31/3, 
and 2014/979-31/1). The first cohort in this paper consisted of 26 patients with liver 
biopsy-confirmed NAFLD. These patients were recruited from the out-patient clinic at 
the Upper GI Tract Department at Karolinska University Hospital, Stockholm. From 
these patients, peripheral blood was collected. As controls, this cohort also included 
peripheral blood from 15 healthy blood donors collected at the blood bank at 
Karolinska University Hospital, Stockholm. A second cohort consisted of 26 patients 
that underwent laparoscopic gastric bypass surgery at Danderyd and Ersta Hospitals in 
Stockholm. From these patients, peripheral blood as well as liver and adipose tissue 
biopsies were collected. 
The study in paper II was approved by the Regional Committees for medical and health 
research ethics in Norway (REK, approval number 2015/2343). The first cohort in this 
study consisted of 57 morbidly obese individuals undergoing bariatric surgery at Voss 
Hospital. These patients donated fasting blood samples as well as subcutaneous and 
visceral adipose tissue biopsies. The samples from this cohort of patients were used for 
analysis by flow cytometry, gene expression analysis and immunohistochemistry. This 
cohort included 10 patients diagnosed with T2D. A second cohort in this study 
consisted of the 57 patients from the first cohort and an additional 10 T2D bariatric 
surgery patients as well as 25 lean volunteers (BMI > 25 kg/m2). The blood samples 
from the lean controls were collected at Haukeland University Hospital. Blood samples 
from this cohort was used for analysis of inflammatory proteins and adipokines. The 
third cohort included 34 of the patients in cohort 2. These were bariatric surgery 
patients that underwent laparoscopic sleeve gastrectomy and that had follow-up blood 
samples taken 3 and 12 months after surgery. Blood samples from this cohort was also 
used to analyze inflammatory proteins and adipokines. 
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In paper III we used liposuction asiprates from patients undergoing plastic surgery. 
This study was approved by the Regional Committees for medical and health research 
ethics (REK, approval number 2010/502). The SVF was isolated and used for surface 
proteome screening. Additionally, buffy coats were used for isolation of PBMC. The 
buffy coat samples were collected from the blood bank at Haukeland University 
Hospital from anonymous donors and the samples were used in the surface proteome 
screening and as control samples for the flow cytometry experiment. The scRNA-seq 
data used in this study was retrieved from a previously published study (150). We only 
included the SAT-dervied cells that were obtained from 13 SAT samples collected 
from 14 individuals undergoing bariatric surgery. 
3.2 Sample preparation 
3.2.1 Isolation of peripheral blood mononuclear cells from blood 
samples 
PBMCs were isolated from heparin blood collected from patients or controls or from 
buffy coats obtained from the blood bank. Isolation was performed using a density 
gradient centrifugation method in which PBS-diluted whole blood/buffy coat was 
carefully layered on top of either Lymphoprep (paper II and III) or Ficoll-Hypaque 
(paper I). After centrifugation at high speed with no brake and acceleration on the 
centrifuge, the leukocyte layer can be extracted. The isolated PBMCs were either used 
immediately for flow cytometry staining or cryopreserved in freezing media consisting 
of 90 % FBS and 10 % DMSO and stored in liquid nitrogen. 
3.2.2 Isolation of the stromal vascular fraction from adipose tissue 
and immune cells from the liver 
The SVF from the adipose tissue was isolated using two similar protocols depending 
on the starting material. Both involved enzymatic digestion of the tissue with either 
collagenase I (AT biopsies, paper II) or II (AT biopsies, paper I) or Liberase 
(liposuction material, paper III), which is a blend of different enzymes used to increase 
the quality of the tissue digestion. Liver biopsies (paper I) were digested using 
collagenase II. Adipose tissue biopsies collected during surgery as well as liver 
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biopsies were minced into smaller pieces before enzyme digestion in order to better 
dissociate the tissue. The smaller SAT and VAT samples obtained during bariatric 
surgery were left to separate in tubes, while the large amount of liposuction aspirates 
from plastic surgery patients were separated in a separating funnel. The SVF was then 
collected from underneath the floating adipocyte layer. 
For paper II and III, the samples were used immediately after purification of the SVF 
as macrophages are fragile cells that are expected to have a rather low recovery rate 
when thawing the cells after cryopreservation (195). 
3.3 Flow cytometry 
Multi-color flow cytometry allows for analysis and characterization of cell populations 
at a single-cell level. Flow cytometry can also be used to assess DNA content of cells 
as well as cell numbers, size and granularity. Cells are usually stained with several 
fluorochrome-labelled antibodies and entered into the flow cytometer where they pass 
by a laser and a detector. As the cells pass through the laser, the scattered light and 
fluorescent signal produced is detected by photomultiplier tubes (PMT). The scattered 
light is in the form of forward scatter (FSC) that is proportional to the cell size, while 
side scatter (SSC) is a measure of the granularity of the cell (196). Most flow 
cytometers are made to detect fluorochromes in 15-18 channels in addition to FCS and 
SSC, however, newer flow cytometers allow analysis of up 50 parameters. 
The emission spectrum of a fluorochrome is wide and, when several fluorochromes 
are used together, spectral overlap may be an issue. This leads to detection of signal 
from one fluorochrome in the detection filter for another fluorochrome. To correct for 
this signal overlap, compensation is performed. This involves staining with one 
antibody at the time to detect signal spillover into other detection channels, that will 
then be subtracted from these channels (196).. In our experiments, we used anti-mouse 
compensation beads, which are polystyrene microparticles that bind to any mouse 
antibodies, as well as beads that do not bind any antibodies, which were used as 
negative control. The beads are single-stained with each of the antibodies in the panel 
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and run on the flow cytometer. In the analysis, the single-stained samples are used to 
create a compensation matrix that is applied on all the samples run afterwards in order 
to compensate for signal spillover from the fluorochromes. 
In this thesis, flow cytometry was used to assess NK cell phenotype and function in 
PBMCs from patients with NAFLD, assess phenotype of liver and AT NK cells from 
NAFLD patients, and phenotype of ATMs from obese patients. Additionally, we 
performed a flow cytometry-based surface proteome screening of monocytes and 
macrophage sin blood and AT as well as preadipocytes from AT. 
The functional panel (described below) included intracellular staining, where after the 
initial staining of the surface proteins, a step involving both fixation and 
permeabilization, using a Fix/Perm buffer, was performed. Then, a second step of 
staining of the intracellular proteins was done. This allowed for staining of cytokines 
produced by the NK cells after the functional assay (described below). For the 
proteome screening, PBMCs and SVF were mixed together during the experiments. In 
order to be able to distinguish the PBMCs and SVF in the subsequent analysis, the 
cells were barcoded. This involved staining with CD45 antibodies, conjugated to 
different fluorochromes. The PBMCs were stained with CD45 BV650, whereas the 
SVF were stained with CD45 A700. 
The flow cytometry data was analyzed using FlowJo, where the cell populations of 
interest are gated on based on their expression of or lack of expression of certain 
markers. High-dimensional data such as flow cytometry data is often visualized using 
an algorithm called t-Distributed Stochastic Neighbor Embedding (tSNE) or a similar 
algorithm called viSNE. This algorithm reduces the dimension of the data by taking 
each datapoints and giving it a location on a two or three-dimensional map (197). Thus, 
the data may be visualized by density plots or overlaying heat maps (198), where the 
phenotypically similar cell subsets tend to cluster together. 
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3.4 Functional NK cell assay 
NK cell functions such as degranulation and cytokine production can be assessed using 
a functional assay. This involves overnight pre-stimulation of PBMCs with 
interleukins such as IL-12 and IL-18. The next day, K562 cells, which are target cells 
for NK cells are added at a ratio of 1:10 in relation to the amount of PBMCs. After 
one hour, protein secretion is inhibited by addition of Golgi plug (Brefelding A) and 
Golgi stop (Monesin). The cells are left for 5 more hours before staining for flow 
cytometric analysis. The ability of the NK cells to produce cytokines such as IFN-γ, 
TNF and MIP-1β, their ability to upregulate CD107a, CD69, CD44 and CD25, and to 
downregulate CD16 in response to the activation with ILs and target cells are then 
measured using flow cytometry. 
3.5 Immunohistochemistry 
Immunohistochemistry (IHC) is a method in which antibodies are used to detect 
specific types of cells in tissue sections. In contrast to flow cytometry, IHC allows for 
determination of tissue distribution and localization of certain antigens or cell types. 
However, using IHC to accurately quantify numbers of cells is not commonly done. 
Additionally, IHC is usually performed on only smaller parts of a tissue biopsy, and 
in thin sections, which may not be representative for the whole tissue as it depends on 
where the biopsy was taken. With flow cytometry, on the other hand, it is possible to 
analyze cells from a whole piece of tissue. 
Formaldehyde or formalin is the gold standard fixative agent for fixing tissue for IHC. 
We fixed fresh AT biopsies in 4 % formalin for 24 hours before transferral to 70 % 
ethanol for storage until further processing. The tissue was then embedded in paraffin 
and sectioned using a microtome. 
One issue with fixation in formalin is over-fixation, which may lead to unmasking of 
antigens. Further, fixation leads to cross-linking of the tissue and this may alter the 
structure of antigens making them hard to detect using antibodies. This obstacle is 
often overcome by introducing a step of antigen retrieval to the protocol, which is 
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often performed when tissue is fixed in formalin. The most common forms of antigen 
retrieval include protease-induced epitope retrieval, heat-induced epitope retrieval or 
retrieval using detergents (199). Our protocol used heat-induced epitope retrieval to 
retrieve the antigens and it involved heating the tissue slides at 98 ºC for 24 minutes 
followed by cooling to 58 ºC in a target retrieval solution. After antigen retrieval, the 
tissue sections were washed and incubated with H2O2 to block endogenous peroxidase 
activity. Then the sections were blocked to avoid unspecific binding of the antibody 
before overnight incubation with the antibody. We used CD68, which is a common 
macrophage marker (200). The next day the sections were washed and incubated with 
the secondary antibody, which was conjugated to horseradish peroxidase. After 
incubation, DAB substrate was added to the section. This substrate reacts with the 
horseradish peroxidase, creating a brown color. The sections were then counterstained 
with hematoxylin that stains cell nuclei blue and imaged using a microscope to 
determine CD68+ macrophages in crown-like structures. Further, the images were 
processed using Image J with the plugin Adiposoft to determine adipocyte diameter 
(201). 
3.6 Quantitative polymerase chain reaction (qPCR) 
In order to analyze whole-tissue gene expression, RNA was extracted from frozen 
adipose tissue biopsies. The RNA was then reverse transcribed to cDNA using reverse 
transcriptase. Real-time qPCR was performed using SYBR Green and the LightCycler 
® 480 system from Roche. SYBR Green is a fluorescent dye that binds to double 
stranded DNA (dsDNA). Upon binding to the dsDNA a fluorescent signal is detected 
that is proportional to the amount of dsDNA and this signal increases as the DNA is 
amplified in the PCR reaction. 
In this study, the relative gene expression was calculated using the delta-delta Ct 
method. The Ct value of the target gene was first normalized to the Ct value of a 
reference gene, giving a ΔCt value for each sample. Then a calibrator was assigned 
and, in our case, this was the average ΔCt for all the SAT samples. The calibrator value 
was then subtracted from the ΔCt value, giving a ΔΔCt value for each sample. The 
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relationship between the Ct value and the amount of original mRNA in the sample is 
inversely and exponential. Thus, the normalized gene expression is calculated as 2-ΔΔCt. 
Lastly, the 2-ΔΔCt values for all the samples were normalized to the average gene 
expression for SAT samples for each of the genes. This gave values for the SAT 
samples at 1 and values for the VAT samples were relative to the SAT samples making 
it easier to compare the expression between SAT and VAT for each gene. 
3.7 Luminex assay 
Luminex allows for simultaneous detection of multiple proteins in a sample. The 
Luminex system is based on magnetic beads coated with antibodies against the analytes 
of interest. Beads that target different analytes may be mixed together. The samples, in 
our case, serum samples were added to the bead mixture and incubated to allow for 
binding of the antibodies to their target. Detection antibodies, with biotin tags, are 
added and bind to the antigen. Then, phycoerythrin (PE)-conjugated streptavidin is 
added, which then binds to the detection antibodies. The sample is read on a detection 
instrument that has two lasers. The first laser is used to classify the bead and thus to 
determine which analyte is detected. The second laser can determine the strength of the 





4. Summary of results 
Paper I 
In this study, we first performed a global assessment of different circulating immune 
cells in patients with NAFLD and NASH and compared this to immune cell populations 
from healthy controls. Few differences were observed in the numbers of B cells, NK 
cells and total, as well as CD4+, CD8+, and γδ T cell populations between healthy 
controls and patients. However, there was a trend towards reduced MAIT cell 
frequencies in NASH patients compared to both healthy controls and NAFLD patients. 
Further, while monocyte and myeloid DCs levels were unchanged, we observed a 
decline in plasmacytoid DCs in NASH patients. 
As NK cells have been implicated in liver inflammation, we assessed circulating and 
tissue-resident NK cell populations in patients with NAFLD and investigated any 
disease-specific changes within these NK cell populations. Phenotypic characterization 
of circulating NK cells revealed no changes in the proportion of CD56bright to CD56dim 
NK cells. Further, neither the disease severity of NAFLD or the presence of obesity 
influenced the surface receptor expression on the circulating NK cells, with the 
exception of NKG2D, which was expressed on higher levels on NK cells from patients 
with NASH. This increase was seen on both CD56bright and CD56dim NK cells and also 
when comparing obese and lean individuals. We also assessed the potential of the 
circulating NK cells to produce cytokines, upregulate CD107a, CD69, CD44 and CD25 
and downregulate CD16 in response to stimulation with IL-15 and IL-18 and/or target 
cells. We found that NK cells from NAFLD and NASH patients had a similar capacity 
for degranulation, cytokine production and upregulation of activation markers as NK 
cells from healthy controls. 
Finally, we characterized liver and AT NK cells from NAFLD and NASH patients. As 
expected, NK cells were enriched in the liver compared to blood and NK cells were 
also detected in the AT. The tissue NK cells had a higher ratio of CD56bright to CD56dim 
NK cells compared to blood, with up to half of all NK cells in the tissues being 
CD56bright NK cells. The frequency of AT and liver NK cells were unaltered in NAFLD 
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and NASH patients, and none of the investigated phenotypic markers showed a clear 
link to either NAFLD disease activity, level of liver fibrosis or the degree of insulin 
resistance (HOMA-IR) of the patients. 
Paper II 
In this study, we characterized adipose tissue macrophages (ATMs) in a cohort of 
morbidly obese subjects and found that while the total number of 
macrophages/monocytes were highest in SAT, VAT harbored more pro-inflammatory 
M1-like macrophages. The pro-inflammatory identity of the M1-like macrophages was 
supported by their expression of surface receptors CCR2, CD44, CD40, and HLA-DR. 
M2-like macrophages, on the other hand, displayed low levels of CCR2 and also 
somewhat higher levels of CD163, which supported their anti-inflammatory identity. 
Further, we investigated the associations between the ATMs and insulin resistance and 
other metabolic parameters. The M1/M2 ratio in both SAT correlated positively with 
HOMA-IR. Further, elevated M1/M2 ratio was associated with dyslipidemia and this 
association seemed to mostly be driven by a correlation between M2-like macrophages 
and triglycerides and HDL cholesterol. We also assessed adipose tissue gene 
expression, measured adipocyte size and the presence of CLS in the AT. There were 
no clear depot-specific differences in the gene expression nor in the number of CLS 
between SAT and VAT and no associations were found between these markers of AT 
inflammation and clinical or biochemical markers of metabolic dysregulation. 
Next, we measured a panel of adipokines and inflammatory factors in serum from lean 
and obese individuals. Most of the measured factors were elevated in obesity and 
distinct factors were associated with biochemical parameters and adipose tissue 
macrophages. Lastly, the same adipokines and inflammatory factors were measured in 
serum from obese individuals at the time of bariatric surgery as well as 3 and 12 months 
after surgery. All of the measured factors changed after bariatric surgery, however, the 
reduction in the inflammatory factors did not correlate significantly with reductions in 
HOMA-IR or other biochemical markers after bariatric surgery. 
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Paper III 
There is a lack of consensus regarding which surface protein that best define M1- and 
M2-like adipose tissue macrophages. Further, there is no clear definition of surface 
proteins that describe adipocyte progenitor cells in humans. Thus, we performed a flow 
cytometry-based surface proteome screening of AT macrophages and progenitors.  
The myeloid cells generally expressed higher levels of the analyzed proteins, however, 
we identified surface markers specific for both the progenitor and myeloid cells. The 
surface proteome was distinct in the CD29+ compared to the CD34+ progenitor 
subpopulation and in the M1-like compared to the M2-like ATMs as well as compared 
to the monocytes. The M1-like macrophages and monocytes were more similar in their 
surface protein expression compared to the M2-like macrophages.  
Further, we used a previously published single-cell RNA sequencing (scRNA-seq) 
dataset to annotate clusters of the progenitor and myeloid cells. The CD34+ progenitor-
specific proteins mapped to one of the progenitor clusters, whereas the CD29+ 
preadipocytes could not be annotated to any of the clusters. One of the two macrophage 
clusters seemed to be enriched for M1-like macrophages, however, this cluster also 
showed upregulation of genes associated with LAMs and MMe’s. Lastly, we combined 
our protein expression data with the scRNA-seq data and explored the local 






NK cell phenotype and function in NAFLD and NASH 
In paper I, we found retained NK cell function in circulating NK cells, however, it 
would also be interesting to assess function of NK cells in liver and AT. Due to limited 
amounts of tissue available, only phenotypic characterization of tissue NK cells was 
performed. Other studies found that human AT NK cells have increased expression of 
activation markers compared to peripheral blood NK cells. AT NK cells expressed 
higher levels of several activation receptors compared to circulating NK cells, and 
amongst these were NKp46 (171). Our results also pointed towards higher expression 
of NKp46 on AT NK cells compared to circulating NK cells, however, this was due to 
the AT containing higher amounts to CD56bright NK cells. Our finding of higher levels 
of CD56bright NK cells in AT compared to blood is in line with findings by others (171). 
Several studies also report increased activation of NK cells as well as alterations in NK 
cell function in obesity (169,174,179). Obesity was associated with increased 
expression of surface receptors CD69 and production of granzyme B, indicating 
increased activation of NK cells. At the same time, the ability of the NK cells to 
degranulate and produce cytokines was reduced (179). In childhood obesity, NK cells 
were also activated compared to normal weight children. Additionally, the NK cells 
showed increased metabolism and a loss of functions such as proliferation and ability 
to lyse tumor cells (174). Another study also showed that obesity was associated with 
reduced function of NK cells due to metabolic paralysis of the cells (169). 
It has been shown that NK cells can kill activated hepatic stellate cells (HSC) in the 
liver through NKG2D signaling in mice (202). A human study showed that NKG2D 
was the only marker investigated that was increased on AT NK cells from obese 
compared to lean individuals (171). Similarly, we found an upregulation of the 
activating receptor NKG2D on circulating NK cells in NASH patients compared to 
lean controls, on both CD56bright and CD56dim NK cells. In contrast to this, however, 
another study found that circulating NK cells from healthy controls had higher 
expression of NKG2D compared to NK cells from NAFLD patients. This increased 
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expression was observed on total NK cells, but also on CD56bright and CD56dim NK 
cells. This study also examined at NKG2D expression on hepatic NK cells, however, 
no difference in the expression of NKG2D was observed between patients with 
NAFLD and healthy controls (203). It is worth mentioning that this study only included 
liver samples from 3 healthy subjects. Our finding of increased expression of NKG2D 
on NK cells from NASH patients could indicate that also in humans, NKG2D might be 
involved in improving liver fibrosis, as is shown in mice (202). 
Some studies have shown that the NKG2D ligands MHC class I chain-related protein 
A and B (MICA/B) are upregulated in the liver of mice with NASH (204). We assessed 
the expression of MICA and MICB on human hepatocytes, however, there was no 
difference in their expression between lean controls and patient samples. Further, we 
did not have the possibility to investigate the expression of NKG2D on NK cells from 
liver or AT. In the human uterus, NK cells are found to interact with macrophages via 
NKG2D on NK cells and MICA, expressed on macrophages (205). NK cells may also 
interact with macrophages in the AT, possibly through NKG2D or other receptors, 
however, this remains to be elucidated. Further, Kupffer cells in the liver has been 
shown to be involved in regulating hepatic NK cell function and phenotype and may 
decrease NK cell activation through their production of IL-10 (206). NK cells are also 
found to be able to regulate macrophage accumulation and phenotype in AT 
(157,158,160). Thus, it may be interesting to assess the expression of NKG2D and 
other activating receptors on NK cells from AT and liver and explore their interactions 
with other cell types, such as macrophages, in these tissues. 
In paper I, we also performed immunophenotyping of the major immune cell subsets 
in PBMC from patients with NAFLD and NASH as well as healthy controls. This 
showed that only plasmacytoid DCs (pDCs) were significantly different between 
healthy controls and patients, with lower pDC levels in patients with NASH compared 
to healthy controls. In mice, liver DCs are found to be increased, which is thought to 
protect the liver from inflammation and fibrosis as DCs are involved in clearance of 
dead cells (207). Indeed, CD103+ DCs specifically are found to improve liver steatosis 
and inflammation (208). Thus, it might be of interest to study DCs in human liver. 
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Another study investigating lymphocyte populations in PBMC and liver from healthy 
controls and NAFLD patients, found that NAFLD patients had increased frequencies 
of several CD4+ and CD8+ T cell subsets, including total CD4+ T cells, compared to 
healthy controls. We did not find any differences in the frequencies of total, CD4+ or 
CD8+ T cells. On the other hand, we did find a trend towards reduced frequency of 
MAIT cells in NASH patients compared to controls. MAIT cells might be an 
interesting cell type to investigate further in terms of obesity and T2D, as obesity and 
T2D are both associated with decreased frequency of circulating MAIT cells (209–
212), and bariatric surgery is associated with increased circulating MAIT cell levels 
(209). MAIT cells are also found to be more abundant in AT compared to blood 
(209,210). AT MAIT cells, but not blood MAIT cells were found to produce the 
cytokine IL-10. However, AT MAIT cells from obese individuals do not produce IL-
10, but rather IL-17, a cytokine associated with insulin resistance (210). Reduced 
circulating MAIT cell levels in obesity is also associated wi th HbA1c and 
inflammatory markers. The decrease in MAIT cell abundance in obesity might be 
explained by elevated blood glucose levels as glucose is found to induce apoptosis of 
MAIT cells in vitro (211). 
MAIT cells from NAFLD patients are found to express higher level of CXCR6 
compared with MAIT cells from healthy controls. This suggests that the MAIT cells 
have a stronger ability to migrate to the liver. Circulating MAIT cells in both healthy 
controls and NAFLD patients are also found to express high levels of CCR5, indicating 
that they have a strong tendency to migrate to both the liver and AT.    
Indeed, NAFLD was associated with increased frequency of MAIT cells in the liver 
and a higher NAFLD activity score was associated with higher levels of liver MAIT 
cells. The MAIT cells in the liver could be activated by Kupffer cells and the MAIT 
cells could also induce polarization of macrophages into a M2-like phenotype in vitro. 
Further, in mice, MAIT cell deficiency was associated with severity of hepatic steatosis 
and inflammation, suggesting that MAIT cells might protect against NAFLD 
inflammation (212). Thus, exploring the role of circulating and tissue MAIT cells in 
relation of obesity and NAFLD might be interesting. 
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ATMs and inflammatory circulating factors in relation to insulin 
resistance 
In paper II, we analyzed ATMs in obese individuals and found that while the total 
number of macrophages and monocytes was higher in SAT, there were more pro-
inflammatory M1-like macrophages in VAT. The literature on depot-specific 
differences in the numbers of ATMs in human obesity is somewhat contradictory, 
where some report higher M1-like macrophage levels in VAT (213,214). In contrast to 
this and to our findings, other studies find that M1-like macrophages are more abundant 
in SAT (141). Thus, the depot-specific differences in frequencies ATM are still not 
entirely clear. 
While Wentworth and colleagues (141) showed that M1-like macrophages (CD11c+ 
CD206+) in the AT localizes to CLS, our data did not indicate an association between 
the numbers of M1-like macrophages detected with flow cytometry and the numbers 
of CLS detected as CD68+ macrophages surrounding adipocytes. CD68, while 
considered a general macrophage marker, might not be the optimal marker for detection 
of ATMs in general or specifically in CLS. A recent scRNA-seq analysis revealed that 
CD68 expression on macrophages varied considerably between individuals and that 
the expression was rather low. In fact, expression of CD68 was only seen on 19-52% 
of all ATMs (215). Others have used macrophage markers such as MAC-2/galectin-
3(216) to detect CLS in adipose tissue. Another point to consider is using markers 
specific for detection of M1- or M2-like macrophages to identify these macrophage 
subsets specifically. Using subset-specific markers allows for identification of their 
localization in the AT and to investigate whether M1-like macrophages do indeed 
localize to CLS. One option is using CD11c, which is expressed on M1- but not M2-
like macrophages. However, CD11c is also a marker of dendritic cells, and thus, a 
combination of markers might be more optimal for detection of different subtypes of 
macrophages and their tissue distribution. An interesting option would include 
immunofluorescent or imaging mass cytometry, which allows for staining with several 
antibodies at the same time. 
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In the analysis of ATMs, we did not examine the patients with T2D separately as only 
10 of the 57 patients in the first cohort were diagnosed with T2D. It would be 
interesting to include more patients with T2D in order to analyze these individuals 
separately. Another issue is the fact that several diabetic drugs are anti-inflammatory 
(217,218) and could therefore influence the results. However, the diabetic group in the 
analysis of circulating factors, did not display levels of the factors that differed from 
the obese groups without T2D. On the other hand, when grouping the prediabetic 
individuals (HbA1c between 39 and 47) together with the T2D individuals, IL-18 was 
the only marker that were different between patients with obesity and patients with 
obesity and prediabetes or T2D. This is in line with findings by others reporting that 
IL-18 is elevated in serum of T2D patients (219) and associated with insulin resistance 
(220) and that higher IL-18 levels are associated with increased risk of developing 
diabetes (221) Thus, this circulating factor may be an interesting marker for T2D and/or 
prediabetes. 
Another issue that potentially could affect the results in this study is the preoperative 
weight loss that the patients may undergo. It has been shown that a slight preoperative 
weight loss prior to bariatric surgery reduces the surgical complications (222). Thus, 
the patients are usually advised to lose weight during the months prior to surgery. The 
preoperative weight loss that the patients may experience could influence the 
inflammatory status at the time of surgery when both AT biopsies and blood samples 
were taken. It is shown that weight loss may influence inflammation in different ways. 
Studies in mice show that elevated levels of total and CD11c+ ATMs persisted for up 
to 6 months following weight loss, even with a loss of fat mass (223). On the other 
hand, others find that while there in an initial increase in ATMs, the numbers of ATMs 
decreased with an extended weight loss period (224). Human data show that 7% weight 
loss after RYGB surgery or lifestyle intervention led to an increase in neutrophil 
numbers and elevated mRNA levels of IL-1β (225), whereas others studies demonstrate 
decreased AT expression of inflammatory genes following bariatric surgery (226). 
Another study reports no change in AT inflammation following surgery-induced 
weight loss after 1 month and even 12 months after surgery, when insulin sensitivity 
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was improved, no changes in pro-inflammatory AT gene expression was observed. 
This suggest that inflammation is a dynamic process that may be affected by length 
and/or pace of the weight loss (227). Another human study demonstrated that rapid 
weight loss after very low-calorie diet increased CLS density in SAT, without changing 
AT gene expression of inflammatory genes. At the same time, the weight loss was 
accompanied by a reduction in hsCRP and glucose levels (228), suggesting that weight 
loss have differential effect on AT and circulating markers of inflammation. This is in 
line with our findings were reductions in serum inflammatory factors do not correlate 
with reduction in insulin resistance (HOMA-IR). 
One limitation of this study is the lack of lean controls in the part that assesses AT 
inflammation. As it is much easier to collect blood compared to AT biopsies from lean 
controls, we only included lean controls in the measurements of circulating 
inflammatory factors. However, after the initial work for this paper was completed, we 
started to receive blood samples and AT biopsies from lean patients undergoing 
cholecystectomy. Individuals with a high BMI are at increased risk of getting gallstones 
(cholelithiasis) or inflammation of the gallbladder (cholecystitis), which may lead to a 
cholecystectomy (229), thus many cholecystectomy patients are overweight or obese. 
Some studies report lower amounts of ATMs in lean cholecystectomy patients 
compared to indiviudals with obesity even when the lean control group had a median 
BMI of 26 kg/m2. Other studies also include lean control groups with BMI < 30 kg/m2 
and show elevated infiltration of macrophages, higher AT gene expression of CC 
chemokines and increased serum concentrations of IL-6 and CRP in individuals with 
obesity compared to lean individuals (230). Thus, it seems as though a lean control 
group with a BMI below 30 kg/m2 might be lean enough to detect differences compared 
to induviduals with obesity. 
In the present study, we characterized ATMs in fresh adipose tissue biopsies directly 
after tissue fractionation as most of the macrophages do not survive after freezing and 
thawing. To get a cohort of patients with varying degrees of insulin resistance we had 
to analyze samples from a large number of patients. Thus, to characterize the degree of 
insulin resistance for these patients was not feasible. Therefore, the insulin resistance 
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status of the patients included in the study were defined by HOMA-IR, using fasting 
insulin and glucose levels, which were measured in fasting blood samples taken the 
day of surgery. HOMA-IR as a measure of insulin resistance has been criticized, 
however, it has been showed that HOMA-IR correlate well with other measures of 
insulin resistance such as the euglycemic clamp (31). 
It has been suggested that insulin resistance of AT precedes insulin resistance in tissues 
such as liver and skeletal muscle, mainly because FFAs released from the AT may 
affect the liver and skeletal muscle and lead to development of insulin resistance. 
Insulin inhibits lipolysis and promotes storage of lipids and if this malfunction, it may 
lead to ectopic fat accumulation and lipotoxicity (231,232). Thus, it may be interesting 
to measure insulin resistance in the AT itself. Several methods have been described to 
quantify AT insulin resistance (232). Plasma levels of FFA or glycerol have been 
proposed as one simple method, however, there are larger inter-individual differences 
in the clearance of FFAs making these measures inaccurate. Another method is a 
multistep insulin clamp used in combination with an FFA tracer that determines a dose-
response relationship between lipolysis rate and plasma insulin levels. This is a time-
consuming method that may take up to 8 hours to perform. The hyperinsulinemic-
euglycemic clamp technique can also be used and is less time-consuming than the 
multistep clamp method. However, this method can easily overestimate the IC50, which 
is the concentration of insulin needed for 50% suppression of lipolysis. Another method 
is using the adipose tissue insulin resistance index (Adipo-IR), which is similar to 
HOMA-IR. Adipo-IR can be calculated based on fasting plasma FFA and insulin 
concentrations (Adipo-IR = FFA x FPI [nmol/L x pmol/L]). It is also found to be 
associated with hepatic fat content as well as ectopic fat accumulation. Patients with 
NASH are found to have increased Adipo-IR compared to total body adiposity-
matched controls (231). The Adipo-IR index is also found to be reproducible and 
correlated with the multistep clamp technique, however, the Adipo-IR was found to be 
more sensitive to age and physical fitness of the individuals (233). 
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Surface proteome screening AT progenitors and macrophages 
In paper 3, we performed a flow cytometry-based surface proteome screening of blood 
monocytes, ATMs and APCs, using the LEGENDScreenTM platform from Biolegend. 
This allowed us to screen for over 300 surface markers on the different cell types and 
subtypes. The LEGENDScreenTM kit can be coupled with a pre-staining of the cells 
that will be examined, allowing for analysis of surface markers on several different cell 
types or specific subtypes of cells, which is what was done in this study. One of the 
benefits of the LEGENDScreenTM is that is allows for extensive screening and thus 
there is a possibility for identification of new surface markers that have not previously 
been decribed. We identified expression of CD85a, CD48, and CD371 on the M1-like 
ATMs, proteins that to our knowledge has not previously been described to be 
expressed on ATMs. These surface markers might therefore define possible new 
subtypes of M1-like ATMs. Other surface markers might postulate specific functions 
to the cell types they are expressed on or serve as potential drug targets.  
One of the challenges with this method is that it requires a large amount of starting 
material in order to have enough cells for analysis of all the markers. As ATMs are not 
abundant in AT, we had to test our backbone panel in order to ensure that we used 
enough cells to start with in order to end up with a sufficient number of macrophages 
in the end. Thus, analyzing rare cell populations using LEGENDScreenTM might be 
challenging and require prior testing to ensure sufficient starting material is used. In 
the study, we focused on the proteins that were differentially expressed between 
subpopulations, e.g. proteins that were highly expressed on CD34+ progenitors and 
expressed at low levels on CD29+ progenitors. However, as we analyzed the percentage 
of cells expressing each marker, a low to medium expression might not indicate low 
overall expression but rather that there are two distinct populations present, one 
population positive for a certain protein and one that is negative for the protein. Hence, 
we do not know if expression of a surface protein on a small population might define 
an important subpopulation. An example of this is CD142+ progenitor cells that was 
found to only make up a small part of the total AT progenitor cells, however, it had 
potential to inhibit adipogenesis of the other progenitor populations in the AT (68). 
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LEGENDScreenTM is also limited to screening of surface proteins and detection of 
intracellular proteins such as transcription factors or signaling molecules is not 
possible. Another limitation to the method is that validation of the protein expression 
is needed as usually material from only one or very few donors is used in the screening. 
It may also be necessary to perform follow-up experiments to determine the function 
of certain markers expressed on a cell type or identify mechanisms behind expression 
or lack of expression of other markers. This may be achieved by performing functional 
or genetic analysis. In this study, it may be of interst to explore the implications of the 
expression of certain surface markers. Accordingly, it might be interesting to explore 
the differentiation potential of the identified progenitors and explore whether certain 
surface proteins define subpopulations that are more or less capable of differentiation 
to mature adipocytes. The protein CD142, for instance, has been shown to be expressed 
on progenitors that are not able to differentiate and that inhibit adipogenesis of other 
protenitors (68) however, it has also been shown to be expressed on progenitors that 
do differentiate (69). We found that this marker was expressed on the CD29+ 
progenitors and thus, it might be of interst to explore the differentiation capacity of 
these progenitors. One of the studies also showed that DPP4+ cells could become 
CD142+ and then undergo adipogenesis, implicating that expression of other markers 
might regulate the function of another protein. Hence, investigating co-expression of 
proteins on the same cell type will also be important to determine the function of 
surface markers, which was not possible to do in the LEGENDscreen-experiment. 
Moreover, CD29+ progenitors are thought to be beige-like (67), which could be an 
interesting venue to explore further. It would then be possible to explore if this is true 
for all CD29+ progenitors or if it is limited to certain supopulations of these APCs that 
are defined by other surface proteins.  
 It is also possible to use a combination of approaches to study the cell populations 
further, giving deeper insight into the different cell types in the AT. One study, for 
example, used a combinaton of LEGENDScreenTM, microarray and liquid 
chromatography-tandem mass spectrometry to study T cells (234). Additionally, new 
methods are developed to combine surface proteome screening with scRNA-
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sequencing allowing for simultaneous analysis of genes and proteins on a single-cell 
level (235).  
In this study, we used a scRNA-seq dataset to validate our surface protein expression 
data obtained from the LEGENDScreenTM. However, we were not able to validate 
expression of all the identified proteins on the specific clusters in the scRNAseq data, 
mostly due to low expression of a lot of the corresponding genes in the scRNAseq 
dataset. The LEGENDScreenTM platform is based on protein expression, where we 
analyze what is actually expressed as opposed to gene expression, which is subjected 
to epigenetics, post-transcriptional modifications etc. Thus, the RNA level is not 
always corresponding to the actual expression of the encoded protein and even if they 
show expression of genes coding for surface proteins, these proteins might not actually 
be expressed on the cell. However, the scRNA-seq can also detect many more genes 
than the protein screening was able to detect, including genes encoding intracellular 
proteins, which was not detect with the LEGENDscreen-method. Protein detection by 
flow cytometry is based on the availablilty of antibodies that target specific proteins, 
so identification of protein is limited by the antibodies included in the kit. The scRNA-
seq, on the other hand, is limited to only the most highly expressed genes, which may 
explain the lack of overlap between our protein expression data and and gene 
expression data from the scRNA-seq.  
An alternative to LEGENDScreenTM is mass cytometry (CyTOF), which allows for 
analysis of a large number of surface markers. While LEGENDScreen can analyze a 
higher number of total proteins, CyTOF can be used to detectct over 50 markers 
simultaneously at a single cell level. CyTOF is similar to flow cytometry, however, the 
antibodies used are conjugated to heavy metal ions rather than fluorochromes. The 
metal ions are detected in a time-of-flight mass spectrometer, which ameliorates the 
need for compensation (236). 
This study is an example of integrating your own data with already exsisting data and 
new methods to complement and explore the data further. Further, it shows that there 
is potential little overlap between protein and gene expresson. Still, development of 
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sequencing methods with increased sequencing depth will allow for better resolution 
of scRNA-seq data. Other methods and combinations of methods may also be used to 
gain a better understanding of the heterogeneity of the AT.   
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6. Conclusions 
In the present study, we characterized innate immune cells in liver and AT in 
individuals with obesity in relation to NAFLD or insulin resistance. We further 
performed a surface proteome screening of ATMs and APCs.  
Patients with NAFLD or NASH did not display altered proportions of CD56bright to 
CD56dim NK cells in their circulation compared to healthy controls, nor was the 
functionality of the NK cells changed. However, NK cells from patients with NASH 
expressed higher levels of the activating receptor NKG2D. Liver and AT NK cells cells 
had a higher ratio of CD56bright to CD56dim NK cells compared to blood, however, none 
of the phenotypic markers investigated were associated with disease severity or the 
level of fibrosis or insulin resistance. 
In obese patients with variying degree of insulin resistance as measured by HOMA-IR, 
we compared SAT and VAT and found that the SAT had a higher frequency of total 
myeloid cells, whereas the VAT had a higher frequency of pro-inflammatory M1-like 
ATMs. The M1/M2 ratio in SAT correlated positively with HOMA-IR as well as to 
dyslipidemia, an association that was driven mostly by a correlation between M2-like 
ATMs and TG and HDL cholesterol. However, no clear depot-specific differences 
were observed in AT gene expression or in the numbers of CLS, and these markers of 
AT inflammation were not related to markers of metabolic dysfunctions. We identified 
circulating inflammatory factors that were elevated in obesity and associated with 
biochemical parameters, however, despite redcutions in these factors after bariatric 
surgery, the reductions were not associated to parallel reductions in HOMA-IR.  
A surface proteome screening of ATMs and APCs revealed distinct surface proteins on 
progenitor and macrophage subpopulations. Comparing the surface protein expression 
to a scRNA-seq dataset showed enrichement of some proteins associated to distinct 
clusters, however, overall the overlap between protein and gene expression was 
moderate. Lastly, we used our surface protein expression data to guide a computational 
tool that can use scRNA-seq data to explore the local interactome of the ATMs and 
APCs based on their cluster-specific gene expression.  
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7. Future perspectives 
While we have studied both phenotype and function of circulating NK cells, we only 
had sufficient amounts of tissue available to characterize the phenotype of NK cells in 
liver and AT. Thus, it would be of interest to also investigate the function of tissue NK 
cells in terms of their ability to produce cytokines and kill target cells as well as study 
their activation state. Further, it would be interesting to more deeply characterize the 
surface receptors repertoire of AT and liver NK cells. Investigating the metabolic 
profile of the NK cells, both circulating and tissue NK cells, would also be interesting 
to pursue. 
In regards to the macrophage study, it would be valuable to analyze ATMs from lean 
controls to compare with the results from the obese individuals. Here it would also be 
possible to include analysis of NK cells in AT from both lean and obese and possibly 
also study both ATMs and AT NK cells from the same individuals. Further, functional 
characterization of different ATM subsets might also be interesting. To achieve this, 
M1- and M2-like macrophages or even subtypes of these macrophages could be sorted 
from the rest of the SVF using FACS. The macrophages can then be stimulated with 
e.g. LPS or AT-specific stimuli such as FFAs and their secretion of cytokines into the 
medium can be analyzed. Additionally, we could investigate the metabolic profile of 
the ATMs. In this study, we also measured whole-tissue gene expression and it would 
be interesting to analyze gene expression in SVF and mature adipocytes or even in 
sorted ATMs to get a more specific overview of the gene expression in the 
macrophages and not just the whole tissue. 
Further, we would like to include more patients with T2D to investigate their AT 
inflammation. It would also be of interest to include more men to be able to study 
gender-specific differences in AT inflammation. In our analysis of circulating factors, 
some of the factors showed opposite patterns in men and women, where e.g. the men 
had increased levels after surgery, while the women had decreased levels, whereas the 
whole group as a whole showed no change. In this study, we were not able to include 
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enough men to be able to group the studied individuals into men and women, but this 
could be done in future studies. 
In regards to the progenitor cells, it will be valuable to validate the surface protein 
expression in several individuals and also in both SAT and VAT samples. Further, it 
might also be interesting to identify the progenitors that are most likely to differentiate 
into mature adipocytes in vitro and thus be able to use this as a cell model for future 
studies. As for the macrophages, we would also like to validate our findings from the 
screening and study these macrophages in SAT and VAT from both lean and obese 
individuals and relate them to the degree of metabolic disease in obese individuals. 
Additionally, we may further characterize the different progenitor and macrophage 
subtypes with regards to their functions and metabolism. 
  
 81 
Source of data 
1.  Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated 
with underweight, overweight, and obesity. J Am Med Assoc. 2005 Apr 
20;293(15):1861–7.  
2.  Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JAE. Adiposity 
as compared with physical activity in predicting mortality among women. N 
Engl J Med. 2004 Dec 23;351(26):2694–703.  
3.  Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health 
effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 
2017 Jul 6;377(1):13–27.  
4.  Obesity and overweight [Internet]. [cited 2020 Apr 6]. Available from: 
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight 
5.  WHO. Obesity: preventing and managing the global epidemic. Report of a 
WHO consultation. . WHO. World Health Organization; 2000.  
6.  Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et 
al. Overweight, obesity, and mortality in a large prospective cohort of persons 
50 to 71 years old. N Engl J Med. 2006 Aug 24;355(8):763–78.  
7.  Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de 
Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-
participant-data meta-analysis of 239 prospective studies in four continents. 
Lancet. 2016 Aug 20;388(10046):776–86.  
8.  Zhang C, Rexrode KM, Van Dam RM, Li TY, Hu FB. Abdominal obesity and 
the risk of all-cause, cardiovascular, and cancer mortality: Sixteen years of 
follow-up in US women. Circulation. 2008 Apr;117(13):1658–67.  
9.  Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to 
the metabolic syndrome. Endocr Rev. 2000;21(6):697–738.  
10.  Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Gil MJ, et al. 
Body adiposity and type 2 diabetes: Increased risk with a high body fat 
percentage even having a normal BMI. Obesity. 2011 Jul;19(7):1439–44.  
11.  Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 
2006 Dec 14;444(7121):881–7.  
12.  Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass 
index explains obesity-related health risk. Am J Clin Nutr. 2004 
Mar;79(3):379–84.  
13.  Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height 
 82
ratio as a screening tool for the prediction of cardiovascular disease and 
diabetes: 05 could be a suitable global boundary value. Nutr Res Rev. 2010 
Dec;23(2):247–69.  
14.  Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al. The 
predictive value of different measures of obesity for incident cardiovascular 
events and mortality. J Clin Endocrinol Metab. 2010;95(4):1777–85.  
15.  Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome - A new world-wide 
definition. A consensus statement from the International Diabetes Federation. 
Vol. 23, Diabetic Medicine. 2006. p. 469–80.  
16.  Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. 
Body fat distribution, incident cardiovascular disease, cancer, and all-cause 
mortality. J Am Coll Cardiol. 2013 Sep 3;62(10):921–5.  
17.  Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, et al. The 
relationship of body mass and fat distribution with incident hypertension: 
Observations from the dallas heart study. J Am Coll Cardiol. 2014;64(10):997–
1002.  
18.  Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat 
storage in heart, blood vessels and kidneys in the pathogenesis of 
cardiovascular diseases. Int J Obes. 2004 Dec;28(SUPPL. 4).  
19.  Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin-dependent 
platelet aggregation and arterial thrombosis suggests a mechanism for 
atherothrombotic disease in obesity. J Clin Invest. 2001;108(10):1533–40.  
20.  Singhal A, Farooqi S, Cole TJ, O’Rahilly S, Fewtrell M, Kattenhorn M, et al. 
Influence of leptin on arterial distensibility: A novel link between obesity and 
cardiovascular disease? Circulation. 2002 Oct 8;106(15):1919–24.  
21.  Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. 
Association of hypoadiponectinemia with impaired vasoreactivity. 
Hypertension. 2003 Sep 1;42(3):231–4.  
22.  Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with 
cardiovascular disease. Vol. 444, Nature. Nature Publishing Group; 2006. p. 
875–80.  
23.  Kasuga M. Insulin resistance and pancreatic β cell failure. J Clin Invest. 2006 
Jul 3;116(7):1756–60.  
24.  Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. 
Global and regional diabetes prevalence estimates for 2019 and projections for 
2030 and 2045: Results from the International Diabetes Federation Diabetes 
Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov 1;157.  
 83 
25.  WHO. Classification of diabetes mellitus. Vol. 21, Clinics in Laboratory 
Medicine. 2019.  
26.  IDF Diabetes Atlas [Internet]. 2019 [cited 2020 Sep 7]. Available from: 
https://www.diabetesatlas.org/en/resources/ 
27.  Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads 
and missing links. Cell. 2012 Mar 2;148(5):852–71.  
28.  Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in 
vivo. In: Methods in Molecular Biology. 2009. p. 221–38.  
29.  Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining 
insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 
2012 Jul;35(7):1605–10.  
30.  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and β-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 
Jul;28(7):412–9.  
31.  Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Vol. 
27, Diabetes Care. 2004. p. 1487–95.  
32.  Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment 
(HOMA) evaluation uses the computer program. Vol. 21, Diabetes Care. 
American Diabetes Association Inc.; 1998. p. 2191–2.  
33.  Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global 
epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of 
prevalence, incidence, and outcomes. Hepatology. 2016 Jul 1;64(1):73–84.  
34.  Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global 
burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. 
Nat Rev Gastroenterol Hepatol. 2018 Jan 1;15(1):11–20.  
35.  Khan RS, Newsome PN. NAFLD in 2017: Novel insights into mechanisms of 
disease progression. Vol. 15, Nature reviews. Gastroenterology & hepatology. 
NLM (Medline); 2018. p. 71–2.  
36.  Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, 
cardiovascular disease or cirrhosis. Vol. 10, Nature Reviews Gastroenterology 
and Hepatology. 2013. p. 330–44.  
37.  Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for 
obesity: New developments in diet, physical activity, and behavior therapy. 
Circulation. 2012 Mar 6;125(9):1157–70.  
38.  Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-
 84
Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 
Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical 
Trials. J Acad Nutr Diet. 2015 Sep 1;115(9):1447–63.  
39.  Nordvik M, Fleiner HF. Legemidler mot overvekt – viktigere å fokusere på 
livsstilsendringer? [Internet]. 2019 [cited 2020 Sep 7]. Available from: 
https://relis.no/content/5066/Legemidler-mot-overvekt--viktigere-a-fokusere-
pa-livsstilsendringer 
40.  Narayanaswami V, Dwoskin LP. Obesity: Current and potential 
pharmacotherapeutics and targets. Vol. 170, Pharmacology and Therapeutics. 
Elsevier Inc.; 2017. p. 116–47.  
41.  Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. 
Weight change and health outcomes at 3 years after bariatric surgery among 
individuals with severe obesity. JAMA - J Am Med Assoc. 
2013;310(22):2416–25.  
42.  Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) 
trial - a prospective controlled intervention study of bariatric surgery. Vol. 273, 
Journal of Internal Medicine. 2013. p. 219–34.  
43.  Helsedirektoratet. Forebygging, utredning og behandling av overvekt og fedme 
hos voksne [Internet]. 2010 [cited 2020 Jul 7]. Available from: 
https://www.helsedirektoratet.no/retningslinjer/overvekt-og-fedme-hos-
voksne/Overvekt og fedme hos voksne – Nasjonal faglig retningslinje for 
forebygging, utredning og behandling.pdf/_/attachment/inline/24ec824b-646d-
4248-951f-
db6b867ce6cb:4e0740b933ffd5bc03c8f0fdcab00b4135fe4ae9/Overvekt og 
fedme hos voksne – Nasjonal faglig retningslinje for forebygging, utredning og 
behandling.pdf 
44.  Hofsø D, Fatima F, Borgeraas H, Birkeland KI, Gulseth HL, Hertel JK, et al. 
Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes 
(Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet 
Diabetes Endocrinol. 2019 Dec 1;7(12):912–24.  
45.  Gudbrandsen OA, Dankel SN, Skumsnes L, Flølo TN, Folkestad OH, Nielsen 
HJ, et al. Short-term effects of Vertical sleeve gastrectomy and Roux-en-Y 
gastric bypass on glucose homeostasis. Sci Rep. 2019 Dec 1;9(1).  
46.  Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose 
homeostasis and type 2 diabetes. Vol. 143, Gastroenterology. W.B. Saunders; 
2012. p. 897–912.  
47.  DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007 May 
24;356(21):2176–83.  
 85 
48.  Kashyap SR, Gatmaitan P, Brethauer S, Schauer P. Bariatric surgery for type 2 
diabetes: Weighing the impact for obese patients. Vol. 77, Cleveland Clinic 
Journal of Medicine. NIH Public Access; 2010. p. 468–76.  
49.  Jakobsen GS, Småstuen MC, Sandbu R, Nordstrand N, Hofsø D, Lindberg M, 
et al. Association of bariatric surgery vs medical obesity treatment with long-
term medical complications and obesity-related comorbidities. JAMA - J Am 
Med Assoc. 2018 Jan 16;319(3):291–301.  
50.  Pierik AS, Coblijn UK, de Raaff CAL, van Veen RN, van Tets WF, van 
Wagensveld BA. Unexplained abdominal pain in morbidly obese patients after 
bariatric surgery. Surg Obes Relat Dis. 2017 Oct 1;13(10):1743–51.  
51.  Gribsholt SB, Pedersen AM, Svensson E, Thomsen R, Richelsen B. Prevalence 
of self-reported symptoms after gastric bypass surgery for obesity. JAMA Surg. 
2016 Jun 1;151(6):504–11.  
52.  Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Vol. 
316, Molecular and Cellular Endocrinology. 2010. p. 129–39.  
53.  Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that 
counts. PLoS Biol. 2008 Sep;6(9):1819–23.  
54.  Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Vol. 
156, Cell. 2014. p. 20–44.  
55.  Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. 
Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011 
Feb;17(2):200–6.  
56.  Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity. 2015 
Mar 1;23(3):512–8.  
57.  Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. In: Journal of 
Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab; 2004. p. 
2548–56.  
58.  Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: Implication of depot 
differences in adipose tissue for obesity complications. Vol. 34, Molecular 
Aspects of Medicine. Mol Aspects Med; 2013. p. 1–11.  
59.  Cawthorn WP, Scheller EL, MacDougald OA. Adipose tissue stem cells meet 
preadipocyte commitment: Going back to the future. Vol. 53, Journal of Lipid 
Research. 2012. p. 227–46.  
60.  Maslowska M H, Sniderman A D, MacLean L D, Cianflone K. Regional 
differences in triacylglycerol synthesis in adipose tissue and in cultured 
preadipocytes. J Lipid Res. 1993;34(2):219–28.  
 86
61.  Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor 
cells from obese and nonobese adult women and from different adipose tissue 
sites. Horm Metab Res. 1988;19(SUPPL.):35–9.  
62.  Niesler CU, Siddle K, Prins JB. Human preadipocytes display a depot-specific 
susceptibility to apoptosis. Diabetes. 1998;47(8):1365–8.  
63.  Macotela Y, Emanuelli B, Mori MA, Gesta S, Schulz TJ, Tseng YH, et al. 
Intrinsic differences in adipocyte precursor cells from different white fat 
depots. Diabetes. 2012 Jul;61(7):1691–9.  
64.  Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, et 
al. Mechanisms and metabolic implications of regional differences among fat 
depots. Cell Metab. 2013 May 7;17(5):644–56.  
65.  Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, et al. PRDM16 
controls a brown fat/skeletal muscle switch. Nature. 2008 Aug 
21;454(7207):961–7.  
66.  Rodeheffer MS, Birsoy K, Friedman JM. Identification of White Adipocyte 
Progenitor Cells In Vivo. Cell. 2008 Oct 17;135(2):240–9.  
67.  Raajendiran A, Ooi G, Bayliss J, O’Brien PE, Schittenhelm RB, Clark AK, et 
al. Identification of Metabolically Distinct Adipocyte Progenitor Cells in 
Human Adipose Tissues. Cell Rep. 2019 Apr 30;27(5):1528-1540.e7.  
68.  Schwalie PC, Dong H, Zachara M, Russeil J, Alpern D, Akchiche N, et al. A 
stromal cell population that inhibits adipogenesis in mammalian fat depots. 
Nature. 2018 Jul 5;559(7712):103–8.  
69.  Merrick D, Sakers A, Irgebay Z, Okada C, Calvert C, Morley MP, et al. 
Identification of a mesenchymal progenitor cell hierarchy in adipose tissue. 
Science (80- ). 2019 Apr 26;364(6438).  
70.  Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of 
energy balance. Vol. 22, Molecular Endocrinology. 2008. p. 1023–31.  
71.  Hube F, Lietz U, Igel M, Jensen PB, Tornqvist H, Joost HG, et al. Difference in 
leptin mRNA levels between omental and subcutaneous abdominal adipose 
tissue from obese humans. Horm Metab Res. 1996 Dec;28(12):690–3.  
72.  Friedman J. The long road to leptin. J Clin Invest. 2016 Dec 1;126(12):4727–
34.  
73.  Farooqi IS, O’Rahilly S. 20 YEARS OF LEPTIN: Human disorders of leptin 
action. J Endocrinol. 2014;223(1):T63-70.  
74.  Funcke J-B, von Schnurbein J, Lennerz B, Lahr G, Debatin K-M, Fischer-
Posovszky P, et al. Monogenic forms of childhood obesity due to mutations in 
 87 
the leptin gene. Mol Cell Pediatr. 2014 Dec;1(1).  
75.  Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. 
Relationship of adiponectin to body fat distribution, insulin sensitivity and 
plasma lipoproteins: Evidence for independent roles of age and sex. 
Diabetologia. 2003 Apr 1;46(4):459–69.  
76.  Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum 
protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 
1995;270(45):26746–9.  
77.  Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin 
expression from human adipose tissue: Relation to obesity, insulin resistance, 
and tumor necrosis factor-α expression. Diabetes. 2003 Jul 1;52(7):1779–85.  
78.  Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et 
al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat 
Med. 2002;8(7):731–7.  
79.  Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018 
Jul 1;8(3):1031–63.  
80.  Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic 
diseases. Vol. 27, Best Practice and Research: Clinical Endocrinology and 
Metabolism. 2013. p. 163–77.  
81.  Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic 
health in human obesity: A matter of oxygen? Front Endocrinol (Lausanne). 
2015;6(APR):55.  
82.  Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann 
O, et al. Dynamics of fat cell turnover in humans. Nature. 2008 Jun 
5;453(7196):783–7.  
83.  Wang QA, Tao C, Gupta RK, Scherer PE. Tracking adipogenesis during white 
adipose tissue development, expansion and regeneration. Nat Med. 2013 
Oct;19(10):1338–44.  
84.  Kim SM, Lun M, Wang M, Senyo SE, Guillermier C, Patwari P, et al. Loss of 
white adipose hyperplastic potential is associated with enhanced susceptibility 
to insulin resistance. Cell Metab. 2014 Dec 2;20(6):1049–58.  
85.  Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its 
Metabolic Consequences, Including Diabetes and Cardiovascular Disease. 
Front Cardiovasc Med. 2020 Feb 25;7.  
86.  Trayhurn P. Hypoxia and Adipocyte Physiology: Implications for Adipose 
Tissue Dysfunction in Obesity. Annu Rev Nutr. 2014 Jul 17;34(1):207–36.  
 88
87.  Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani 
S, et al. Hypoxia-Inducible Factor 1α Induces Fibrosis and Insulin Resistance in 
White Adipose Tissue. Mol Cell Biol. 2009 Aug 15;29(16):4467–83.  
88.  Wang T, Liu H, Lian G, Zhang S-Y, Wang X, Jiang C. HIF1α-Induced 
Glycolysis Metabolism Is Essential to the Activation of Inflammatory 
Macrophages. Mediators Inflamm. 2017;2017:9029327.  
89.  Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded 
protein response. Nat Rev Mol Cell Biol. 2007 Jul;8(7):519–29.  
90.  Özcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Özdelen E, et al. 
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. 
Science (80- ). 2004 Oct 15;306(5695):457–61.  
91.  Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: 
Inflammation, fibrosis, and impaired angiogenesis. Vol. 127, Journal of 
Clinical Investigation. American Society for Clinical Investigation; 2017. p. 
74–82.  
92.  Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang 
Z V., et al. Adipocyte inflammation is essential for healthy adipose tissue 
expansion and remodeling. Cell Metab. 2014 Jul 1;20(1):103–18.  
93.  Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 
2000;106(4):473–81.  
94.  Saltiel AR. New perspectives into the molecular pathogenesis and treatment of 
type 2 diabetes. Cell. 2001 Feb 23;104(4):517–29.  
95.  Delves PJ, Roitt IM. The immune system. First of two parts. Vol. 343, New 
England Journal of Medicine. 2000. p. 37–49.  
96.  Caputa G, Castoldi A, Pearce EJ. Metabolic adaptations of tissue-resident 
immune cells. Nat Immunol. 2019 Jul 1;20(7):793–801.  
97.  Charles A Janeway J, Travers P, Walport M, Shlomchik MJ. The components 
of the immune system. In: Immunobiology: The Immune System in Health and 
Disease. 5th ed. Garland Science; 2001.  
98.  Trowbridge IS, Thomas ML. CD45: An Emerging Role as a Protein Tyrosine 
Phosphatase Required for Lymphocyte Activation and Development. Annu Rev 
Immunol. 1994 Apr;12(1):85–116.  
99.  Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate 
lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol. 2013 
Feb;13(2):145–9.  
100.  Mazzurana L, Rao A, Van Acker A, Mjösberg J. The roles for innate lymphoid 
 89 
cells in the human immune system. Vol. 40, Seminars in Immunopathology. 
Springer Verlag; 2018. p. 407–19.  
101.  Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell 
CD16 surface expression and function is regulated by a disintegrin and 
metalloprotease-17 (ADAM17). Blood. 2013 May 2;121(18):3599–608.  
102.  Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural 
killer cells in human peripheral tissues. Nat Rev Immunol. 2016 Apr 
28;16(5):310–20.  
103.  Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell 
death pathway. Nat Rev Immunol. 2002 Oct;2(10):735–47.  
104.  Schenkel JM, Masopust D. Tissue-resident memory T cells. Vol. 41, Immunity. 
Cell Press; 2014. p. 886–97.  
105.  Chou C, Li MO. Tissue-resident lymphocytes across innate and adaptive 
lineages. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018.  
106.  Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses 
and inflammation-associated diseases in organs. Vol. 9, Oncotarget. Impact 
Journals LLC; 2018. p. 7204–18.  
107.  Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. Cell. 
2010 Mar;140(6):805–20.  
108.  Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, et 
al. Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron 
Transport Chain to Polarize Macrophages for Tissue Repair. Cell Metab. 2019 
Feb 5;29(2):443-456.e5.  
109.  Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, et al. 
Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 
with apoptotic cells. Science (80- ). 2017 Jun 9;356(6342):1072–6.  
110.  Kammoun HL, Kraakman MJ, Febbraio MA. Adipose tissue inflammation in 
glucose metabolism. Vol. 15, Reviews in Endocrine and Metabolic Disorders. 
Kluwer Academic Publishers; 2014. p. 31–44.  
111.  Nguyen KD, Qiu Y, Cui X, Goh YPS, Mwangi J, David T, et al. Alternatively 
activated macrophages produce catecholamines to sustain adaptive 
thermogenesis. Nature. 2011 Dec 1;480(7375):104–8.  
112.  Huang SC-C, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. 
Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is 
Essential for Macrophage Alternative Activation. Immunity. 2016 Oct 
18;45(4):817–30.  
 90
113.  Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, 
Mukundan L, et al. Macrophage-specific PPARγ controls alternative activation 
and improves insulin resistance. Nature. 2007 Jun 28;447(7148):1116–20.  
114.  Gao M, Zhang C, Ma Y, Bu L, Yan L, Liu D. Hydrodynamic delivery of 
mIL10 gene protects mice from high-fat diet-induced obesity and glucose 
intolerance. Mol Ther. 2013;21(10):1852–61.  
115.  Kowalski GM, Nicholls HT, Risis S, Watson NK, Kanellakis P, Bruce CR, et 
al. Deficiency of haematopoietic-cell-derived IL-10 does not exacerbate high-
fat-diet-induced inflammation or insulin resistance in mice. Diabetologia. 2011 
Apr;54(4):888–99.  
116.  Rajbhandari P, Thomas BJ, Feng AC, Hong C, Wang J, Vergnes L, et al. IL-10 
Signaling Remodels Adipose Chromatin Architecture to Limit Thermogenesis 
and Energy Expenditure. Cell. 2018 Jan 11;172(1–2):218-233.e17.  
117.  Fischer K, Ruiz HH, Jhun K, Finan B, Oberlin DJ, Van Der Heide V, et al. 
Alternatively activated macrophages do not synthesize catecholamines or 
contribute to adipose tissue adaptive thermogenesis. Nat Med. 2017 May 
1;23(5):623–30.  
118.  Plitas G, Rudensky AY. Regulatory T cells: Differentiation and function. 
Cancer Immunol Res. 2016 Sep 1;4(9):721–5.  
119.  Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but 
not obese, fat is enriched for a unique population of regulatory T cells that 
affect metabolic parameters. Nat Med. 2009 Aug;15(8):930–9.  
120.  Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-γ is a 
major driver of the accumulation and phenotype of adipose tissue T reg cells. 
Nature. 2012 Jun 28;486(7404):549–53.  
121.  Kohlgruber AC, Gal-Oz ST, Lamarche NM, Shimazaki M, Duquette D, 
Nguyen HN, et al. γδ T cells producing interleukin-17A regulate adipose 
regulatory T cell homeostasis and thermogenesis. Nat Immunol. 2018 May 
1;19(5):464–74.  
122.  Goldberg EL, Shchukina I, Asher JL, Sidorov S, Artyomov MN, Dixit VD. 
Ketogenesis activates metabolically protective γδ T cells in visceral adipose 
tissue. Nat Metab. 2020 Jan 1;2(1):50–61.  
123.  Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, Lester C, et al. 
Regulatory iNKT cells lack expression of the transcription factor PLZF and 
control the homeostasis of T reg cells and macrophages in adipose tissue. Nat 
Immunol. 2015 Dec 18;16(1):85–95.  
124.  Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al. 
 91 
Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and 
Metabolic Disorder through Regulatory Cytokine Production. Immunity. 2012 
Sep 21;37(3):574–87.  
125.  Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor 
necrosis factor-α: Direct role in obesity-linked insulin resistance. Science (80- 
). 1993;259(5091):87–91.  
126.  Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from 
obesity-induced insulin resistance in mice lacking TNF- α function. Nature. 
1997;389(6651):610–4.  
127.  Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. 
Obesity is associated with macrophage accumulation in adipose tissue. J Clin 
Invest. 2003 Dec 15;112(12):1796–808.  
128.  Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic 
inflammation in fat plays a crucial role in the development of obesity-related 
insulin resistance. J Clin Invest. 2003 Dec 15;112(12):1821–30.  
129.  Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of 
CD11c-Positive Cells Normalizes Insulin Sensitivity in Obese Insulin Resistant 
Animals. Cell Metab. 2008 Oct 8;8(4):301–9.  
130.  Solinas G, Karin M. JNK1 and IKKβ: molecular links between obesity and 
metabolic dysfunction. FASEB J. 2010 Aug;24(8):2596–611.  
131.  Nguyen MTA, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. 
A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is 
activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent 
pathways. J Biol Chem. 2007 Nov 30;282(48):35279–92.  
132.  Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, 
et al. The NLRP3 inflammasome instigates obesity-induced inflammation and 
insulin resistance. Nat Med. 2011 Feb;17(2):179–89.  
133.  McNelis JC, Olefsky JM. Macrophages, Immunity, and Metabolic Disease. 
Vol. 41, Immunity. Cell Press; 2014. p. 36–48.  
134.  Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, et al. Lipid-
Associated Macrophages Control Metabolic Homeostasis in a Trem2-
Dependent Manner. Cell. 2019 Jul 25;178(3):686-698.e14.  
135.  Chen A, Mumick S, Zhang C, Lamb J, Dai H, Weingarth D, et al. Diet 
induction of monocyte chemoattractant protein-1 and its impact on obesity. 
Obes Res. 2005;13(8):1311–20.  
136.  Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa KI, Kitazawa R, et al. MCP-1 
contributes to macrophage infiltration into adipose tissue, insulin resistance, 
 92
and hepatic steatosis in obesity. J Clin Invest. 2006 Jun 1;116(6):1494–505.  
137.  Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, et al. 
Overexpression of monocyte chemoattractant protein-1 in adipose tissues 
causes macrophage recruitment and insulin resistance. J Biol Chem. 2006 Sep 
8;281(36):26602–14.  
138.  Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC, et al. 
Local proliferation of macrophages contributes to obesity-associated adipose 
tissue inflammation. Cell Metab. 2014 Jan 7;19(1):162–71.  
139.  Zheng C, Yang Q, Cao J, Xie N, Liu K, Shou P, et al. Local proliferation 
initiates macrophage accumulation in adipose tissue during obesity. Cell Death 
Dis. 2016;7(3).  
140.  Haase J, Weyer U, Immig K, Klöting N, Blüher M, Eilers J, et al. Local 
proliferation of macrophages in adipose tissue during obesity-induced 
inflammation. Diabetologia. 2014 Mar;57(3):562–71.  
141.  Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. 
Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated 
with insulin resistance in human obesity. Diabetes. 2010 Jul 1;59(7):1648–56.  
142.  Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in 
adipose tissue macrophage polarization. J Clin Invest. 2007 Jan 4;117(1):175–
84.  
143.  Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The 
chemokine system in diverse forms of macrophage activation and polarization. 
Vol. 25, Trends in Immunology. Trends Immunol; 2004. p. 677–86.  
144.  Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages 
in obesity. Immunology. 2018 Dec 1;155(4):407–17.  
145.  Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, et al. Human 
adipose tissue macrophages are of an anti-inflammatory phenotype but capable 
of excessive pro-inflammatory mediator production. Int J Obes (Lond). 2007 
Sep;31(9):1420–8.  
146.  Li P, Lu M, Nguyen MTA, Bae EJ, Chapman J, Feng D, et al. Functional 
heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced 
obese mice. J Biol Chem. 2010 May 14;285(20):15333–45.  
147.  Subramanian S, Pallati PK, Rai V, Sharma P, Agrawal DK, Nandipati KC. 
Increased expression of triggering receptor expressed on myeloid cells-1 in the 
population with obesity and insulin resistance. Obesity. 2017 Mar 1;25(3):527–
38.  
148.  Subramanian S, Pallati PK, Sharma P, Agrawal DK, Nandipati KC. Significant 
 93 
association of TREM-1 with HMGB1, TLRs and RAGE in the pathogenesis of 
insulin resistance in obese diabetic populations. Am J Transl Res. 
2017;9(7):3224–44.  
149.  Hill DA, Lim HW, Kim YH, Ho WY, Foong YH, Nelson VL, et al. Distinct 
macrophage populations direct inflammatory versus physiological changes in 
adipose tissue. Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5096–105.  
150.  Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et 
al. Single-cell analysis of human adipose tissue identifies depot- and disease-
specific cell types. Nat Metab. 2020 Jan 1;2(1):97–109.  
151.  Liu C, Li P, Li H, Wang S, Ding L, Wang H, et al. TREM2 regulates obesity-
induced insulin resistance via adipose tissue remodeling in mice of high-fat 
feeding. J Transl Med. 2019 Sep 2;17(1):300.  
152.  Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. 
Metabolic dysfunction drives a mechanistically distinct proinflammatory 
phenotype in adipose tissue macrophages. Cell Metab. 2014 Oct 7;20(4):614–
25.  
153.  Coats BR, Schoenfelt KQ, Barbosa-Lorenzi VC, Peris E, Cui C, Hoffman A, et 
al. Metabolically Activated Adipose Tissue Macrophages Perform Detrimental 
and Beneficial Functions during Diet-Induced Obesity. Cell Rep. 2017 Sep 
26;20(13):3149–61.  
154.  Xu X, Grijalva A, Skowronski A, Van Eijk M, Serlie MJ, Ferrante AW. 
Obesity activates a program of lysosomal-dependent lipid metabolism in 
adipose tissue macrophages independently of classic activation. Cell Metab. 
2013 Dec 3;18(6):816–30.  
155.  Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, et al. 
Identification of a novel macrophage phenotype that develops in response to 
atherogenic phospholipids via Nrf2. Circ Res. 2010 Sep 17;107(6):737–46.  
156.  Serbulea V, Upchurch CM, Schappe MS, Voigt P, DeWeese DE, Desai BN, et 
al. Macrophage phenotype and bioenergetics are controlled by oxidized 
phospholipids identified in lean and obese adipose tissue. Proc Natl Acad Sci U 
S A. 2018 Jul 3;115(27):E6254–63.  
157.  Lee BC, Kim MS, Pae M, Yamamoto Y, Eberlé D, Shimada T, et al. Adipose 
Natural Killer Cells Regulate Adipose Tissue Macrophages to Promote Insulin 
Resistance in Obesity. Cell Metab. 2016 Apr 12;23(4):685–98.  
158.  Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S, et 
al. NK cells link obesity-induced adipose stress to inflammation and insulin 
resistance. Nat Immunol. 2015 Mar 19;16(4):376–85.  
 94
159.  Wouters K, Gaens K, Bijnen M, Verboven K, Jocken J, Wetzels S, et al. 
Circulating classical monocytes are associated with CD11c+ macrophages in 
human visceral adipose tissue. Sci Rep. 2017 Feb 15;7.  
160.  O’Rourke RW, Meyer KA, Neeley CK, Gaston GD, Sekhri P, Szumowski M, 
et al. Systemic NK cell ablation attenuates intra-abdominal adipose tissue 
macrophage infiltration in murine obesity. Obesity. 2014 Oct 1;22(10):2109–
14.  
161.  O’Sullivan TE, Rapp M, Fan X, Weizman O El, Bhardwaj P, Adams NM, et al. 
Adipose-Resident Group 1 Innate Lymphoid Cells Promote Obesity-Associated 
Insulin Resistance. Immunity. 2016;45(2):428–41.  
162.  Goldszmid RS, Caspar P, Rivollier A, White S, Dzutsev A, Hieny S, et al. NK 
Cell-Derived Interferon-γ Orchestrates Cellular Dynamics and the 
Differentiation of Monocytes into Dendritic Cells at the Site of Infection. 
Immunity. 2012 Jun 29;36(6):1047–59.  
163.  O’Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X, et al. 
Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice. 
Metabolism. 2012 Aug;61(8):1152–61.  
164.  Boulenouar S, Michelet X, Duquette D, Alvarez D, Hogan AE, Dold C, et al. 
Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis 
through Targeted Cytotoxicity. Immunity. 2017 Feb 21;46(2):273–86.  
165.  Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of Ligands for 
the NKG2D Activating Receptor. Annu Rev Immunol. 2013 Mar 
21;31(1):413–41.  
166.  Roan F, Ziegler SF. Human Group 1 Innate Lymphocytes Are Negative for 
Surface CD3ε but Express CD5. Vol. 46, Immunity. Cell Press; 2017. p. 758–9.  
167.  O’Shea D, Cawood TJ, O’Farrelly C, Lynch L. Natural killer cells in obesity: 
Impaired function and increased susceptibility to the effects of cigarette smoke. 
PLoS One. 2010 Jan 25;5(1).  
168.  Jahn J, Spielau M, Brandsch C, Stangl GI, Delank K, Bähr I, et al. Decreased 
NK cell functions in obesity can be reactivated by fat mass reduction. Obesity. 
2015 Nov 1;23(11):2233–41.  
169.  Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, et al. 
Metabolic reprogramming of natural killer cells in obesity limits antitumor 
responses. Nat Immunol. 2018 Dec 1;19(12):1330–40.  
170.  Shoae-Hassani A, Behfar M, Mortazavi-Tabatabaei SA, Ai J, Mohseni R, 
Hamidieh AA. Natural killer cells from the subcutaneous adipose tissue 
underexpress the NKp30 and NKp44 in obese persons and are less active 
 95 
against major histocompatibility complex class i non-expressing neoplastic 
cells. Front Immunol. 2017 Nov 7;8(NOV).  
171.  O’Rourke RW, Gaston GD, Meyer KA, White AE, Marks DL. Adipose tissue 
NK cells manifest an activated phenotype in human obesity. Metabolism. 2013 
Nov;62(11):1557–61.  
172.  Gua H, Xu B, Gao L, Sun X, Qu X, Li X, et al. High frequency of activated 
natural killer and natural killer T-cells in patients with new onset of type 2 
diabetes mellitus. Exp Biol Med. 2012 May;237(5):556–62.  
173.  Theurich S, Tsaousidou E, Hanssen R, Lempradl AM, Mauer J, Timper K, et 
al. IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell 
Subpopulation Deteriorates Energy and Glucose Homeostasis. Cell Metab. 
2017 Jul 5;26(1):171-184.e6.  
174.  Tobin LM, Mavinkurve M, Carolan E, Kinlen D, O’Brien EC, Little MA, et al. 
NK cells in childhood obesity are activated, metabolically stressed, and 
functionally deficient. JCI Insight. 2017 Dec 21;2(24).  
175.  Lynch LA, O’Connell JM, Kwasnik AK, Cawood TJ, O’Farrelly C, O’Shea 
DB. Are natural killer cells protecting the metabolically healthy obese patient? 
Obesity. 2009 Mar;17(3):601–5.  
176.  Caspar-Bauguil S, Cousin B, Galinier A, Segafredo C, Nibbelink M, André M, 
et al. Adipose tissues as an ancestral immune organ: Site-specific change in 
obesity. FEBS Lett. 2005 Jul 27;579(17):3487–92.  
177.  Duffaut C, Galitzky J, Lafontan M, Bouloumié A. Unexpected trafficking of 
immune cells within the adipose tissue during the onset of obesity. Biochem 
Biophys Res Commun. 2009 Jul 10;384(4):482–5.  
178.  Caspar-Bauguil S, Cousin B, André M, Nibbelink M, Galinier A, Periquet B, et 
al. Weight-dependent changes of immune system in adipose tissue: Importance 
of leptin. Exp Cell Res. 2006 Jul 15;312(12):2195–202.  
179.  Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, et al. Alteration 
of Natural Killer cell phenotype and function in obese individuals. Clin 
Immunol. 2017 Apr 1;177:12–7.  
180.  Bähr I, Spielmann J, Quandt D, Kielstein H. Obesity-Associated Alterations of 
Natural Killer Cells and Immunosurveillance of Cancer. Front Immunol. 2020 
Mar 13;11.  
181.  Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat 
Immunol. 2012 Aug;13(8):707–12.  
182.  Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in 
adipocytes by altering expression of signaling and glucose transport proteins. 
 96
Am J Physiol - Endocrinol Metab. 2007 Jan;292(1).  
183.  Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, et al. Serine 
phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. 
J Biol Chem. 2002 Dec 13;277(50):48115–21.  
184.  Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A 
central, role for JNK in obesity and insulin resistance. Nature. 2002 Nov 
21;420(6913):333–6.  
185.  Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 
2005 May 2;115(5):1111–9.  
186.  Chen CY, Del Gatto-Konczak F, Wu Z, Karin M. Stabilization of interleukin-2 
mRNA by the c-Jun NH2-terminal kinase pathway. Science (80- ). 1998 Jun 
19;280(5371):1945–9.  
187.  Chen Q, Wang H, Liu Y, Song Y, Lai L, Han Q, et al. Inducible microRNA-
223 down-regulation promotes TLR-triggered IL-6 and IL-1β production in 
macrophages by targeting STAT3. PLoS One. 2012 Aug 24;7(8).  
188.  Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP 
genes in 3T3-L1 adipocytes by tumor necrosis factor-α. J Biol Chem. 
1991;266(32):21839–45.  
189.  Ye J. Regulation of PPARγ function by TNF-α. Biochem Biophys Res 
Commun. 2008 Sep 26;374(3):405–8.  
190.  Fox TE, Houck KL, O’Neill SM, Nagarajan M, Stover TC, Pomianowski PT, 
et al. Ceramide recruits and activates protein kinase C ζ (PKCζ) within 
structured membrane microdomains. J Biol Chem. 2007 Apr 
27;282(17):12450–7.  
191.  Reali F, Morine MJ, Kahramanoä Ullarl O, Raichur S, Schneider HC, Crowther 
D, et al. Mechanistic interplay between ceramide and insulin resistance. Sci 
Rep. 2017 Jan 23;7.  
192.  Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. 
Diabetes. 1992 Oct;41(SUPPL. 2):97–101.  
193.  Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 
(FABP4): Pathophysiological insights and potent clinical biomarker of 
metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2014 Dec 
16;2014:23–33.  
194.  Fernø J, Strand K, Mellgren G, Stiglund N, Björkström NK. Natural Killer 
Cells as Sensors of Adipose Tissue Stress. Vol. 31, Trends in Endocrinology 
and Metabolism. Elsevier Inc.; 2020. p. 3–12.  
 97 
195.  Hem E, Munthe-Kaas AC. Freezing of rat macrophages. Cryobiology. 
1977;14(6):649–52.  
196.  Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic 
principles and applications. Vol. 37, Critical Reviews in Biotechnology. Taylor 
and Francis Ltd; 2017. p. 163–76.  
197.  Van Der Maaten L, Hinton G. Visualizing Data using t-SNE. J Mach Learn 
Res. 2008;9:2579–605.  
198.  Acuff N V., Linden J.  Using Visualization of t -Distributed Stochastic 
Neighbor Embedding To Identify Immune Cell Subsets in Mouse Tumors . J 
Immunol. 2017 Jun 1;198(11):4539–46.  
199.  Ramos-Vara JA. Principles and methods of immunohistochemistry. Methods 
Mol Biol. 2011;691:83–96.  
200.  Kunz-Schughart L A, Weber A, Rehli M, Gottfried E, Brockhoff G, Krause S 
W, et al. The “classical” macrophage marker CD68 is strongly expressed in 
primary human fibroblasts. Verh Dtsch Ges Pathol.  
201.  Galarraga M, Campión J, Munõz-Barrutia A, Boqué N, Moreno H, Martínez 
JA, et al. Adiposoft: Automated software for the analysis of white adipose 
tissue cellularity in histological sections. J Lipid Res. 2012 Dec;53(12):2791–6.  
202.  Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells 
ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent 
and tumor necrosis factor-related apoptosis-inducing ligand-dependent 
manners. Gastroenterology. 2006;130(2):435–52.  
203.  Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, et al. 
Characterization of the immune cell landscape of patients with NAFLD. PLoS 
One. 2020;15(3).  
204.  Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak 
M, Fingas CD, et al. Major histocompatibility complex class I-related chains A 
and B (MIC A/B): A novel role in nonalcoholic steatohepatitis. Hepatology. 
2010 Jan;51(1):92–102.  
205.  Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, et al. 
Human uterine NK cells interact with uterine macrophages via NKG2D upon 
stimulation with PAMPs. Am J Reprod Immunol. 2009;61(1):52–61.  
206.  Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of 
natural killer cells. Nat Rev Immunol. 2011 Oct;11(10):658–71.  
207.  Henning JR, Graffeo CS, Rehman A, Fallon NC, Zambirinis CP, Ochi A, et al. 
Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in 
mice. Hepatology. 2013 Aug;58(2):589–602.  
 98
208.  Heier EC, Meier A, Julich-Haertel H, Djudjaj S, Rau M, Tschernig T, et al. 
Murine CD103+ dendritic cells protect against steatosis progression towards 
steatohepatitis. J Hepatol. 2017 Jun 1;66(6):1241–50.  
209.  Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, et al. 
Mucosal-associated invariant T cell alterations in obese and type 2 diabetic 
patients. J Clin Invest. 2015 Apr 1;125(4):1752–62.  
210.  Carolan E, Tobin LM, Mangan BA, Corrigan M, Gaoatswe G, Byrne G, et al. 
Altered Distribution and Increased IL-17 Production by Mucosal-Associated 
Invariant T Cells in Adult and Childhood Obesity. J Immunol. 2015 Jun 
15;194(12):5775–80.  
211.  Touch S, Assmann KE, Aron-Wisnewsky J, Marquet F, Rouault C, Fradet M, 
et al. Mucosal-associated invariant T (MAIT) cells are depleted and prone to 
apoptosis in cardiometabolic disorders. FASEB J. 2018 Sep 1;32(9):5078–89.  
212.  Li Y, Huang B, Jiang X, Chen W, Zhang J, Wei Y, et al. Mucosal-associated 
invariant T cells improve nonalcoholic fatty liver disease through regulating 
macrophage Polarization. Front Immunol. 2018 Sep 4;9(SEP).  
213.  Harman-Boehm I, Blüher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, 
et al. Macrophage Infiltration into Omental Versus Subcutaneous Fat across 
Different Populations: Effect of Regional Adiposity and the Comorbidities of 
Obesity. J Clin Endocrinol Metab. 2007 Jun 1;92(6):2240–7.  
214.  Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, et al. 
Increased infiltration of macrophages in omental adipose tissue is associated 
with marked hepatic lesions in morbid human obesity. Diabetes. 
2006;55(6):1554–61.  
215.  Vijay J, Gauthier M-F, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et 
al. Single-cell analysis of human adipose tissue identifies depot and disease 
specific cell types. Nat Metab. 2020 Jan 1;2(1):97–109.  
216.  Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, et 
al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral 
fat depots of genetically obese mice. J Lipid Res. 2008;49(7):1562–8.  
217.  Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents 
in the treatment of diabetes and its vascular complications. Diabetes Care. 2016 
Aug 1;39:S244–52.  
218.  Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-
inflammatory properties of antidiabetic agents providing protective effects 
against vascular complications in diabetes. J Cell Physiol. 2019 Jun 
1;234(6):8286–94.  
 99 
219.  Zaharieva E, Kamenov Z, Velikova T, Tsakova A, El-Darawish Y, Okamura H. 
Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune 
diabetes. Endocr Connect. 2018 Jan 1;7(1):179–85.  
220.  Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated 
plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and 
non-diabetic humans. Clin Immunol. 2005 Nov;117(2):152–60.  
221.  Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-
18 and the risk of type 2 diabetes in women. Diabetologia. 2009 
Oct;52(10):2101–8.  
222.  Benotti PN, Still CD, Wood GC, Akmal Y, King H, El Arousy H, et al. 
Preoperative weight loss before bariatric surgery. Arch Surg. 2009 
Dec;144(12):1150–5.  
223.  Zamarron BF, Mergian TA, Cho KW, Martinez-Santibanez G, Luan D, Singer 
K, et al. Macrophage proliferation sustains adipose tissue inflammation in 
formerly obese mice. Diabetes. 2017 Feb 1;66(2):392–406.  
224.  Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, et al. Weight 
loss and lipolysis promote a dynamic immune response in murine adipose 
tissue. J Clin Invest. 2010 Oct 1;120(10):3466–79.  
225.  Kratz M, Hagman DK, Kuzma JN, Foster-Schubert KE, Chan CP, Stewart S, et 
al. Improvements in glycemic control after gastric bypass occur despite 
persistent adipose tissue inflammation. Obesity. 2016 Jul 1;24(7):1438–45.  
226.  Dankel SN, Fadnes DJ, Stavrum AK, Stansberg C, Holdhus R, Hoang T, et al. 
Switch from stress response to homeobox transcription factors in adipose tissue 
after profound fat loss. PLoS One. 2010;5(6).  
227.  Hagman DK, Larson I, Kuzma JN, Cromer G, Makar K, Rubinow KB, et al. 
The short-term and long-term effects of bariatric/metabolic surgery on 
subcutaneous adipose tissue inflammation in humans. Metabolism. 2017 May 
1;70:12–22.  
228.  Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, et al. 
Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation 
and Metabolism in Obese Postmenopausal Women. J Endocr Soc. 2017 Jun 
1;1(6):625–37.  
229.  Sidhu RS, Raj PK, Treat RC, Scarcipino MA, Tarr SM. Obesity as a factor in 
laparoscopic cholecystectomy. Surg Endosc Other Interv Tech. 2007 
May;21(5):774–6.  
230.  Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, et al. CC 
chemokine and CC chemokine receptor profiles in visceral and subcutaneous 
 100
adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 
2008;93(8):3215–21.  
231.  Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker 
S, et al. Importance of changes in adipose tissue insulin resistance to 
histological response during thiazolidinedione treatment of patients with 
nonalcoholic steatohepatitis. Hepatology. 2009;50(4):1087–93.  
232.  Søndergaard E, Jensen MD. Quantification of adipose tissue insulin sensitivity. 
J Investig Med. 2016;64(5):989–91.  
233.  Søndergaard E, De Ycaza AEE, Morgan-Bathke M, Jensen MD. How to 
measure adipose tissue insulin sensitivity. J Clin Endocrinol Metab. 2017 Apr 
1;102(4):1193–9.  
234.  Graessel A, Hauck SM, Von Toerne C, Kloppmann E, Goldberg T, 
Koppensteiner H, et al. A combined omics approach to generate the surface 
atlas of human naive CD4+ T cells during early T-cell receptor activation. Mol 
Cell Proteomics. 2015 Aug 1;14(8):2085–102.  
235.  Mair F, Erickson JR, Voillet V, Simoni Y, Bi T, Tyznik AJ, et al. A Targeted 
Multi-omic Analysis Approach Measures Protein Expression and Low-
Abundance Transcripts on the Single-Cell Level. Cell Rep. 2020 Apr 7;31(1).  
236.  Ijsselsteijn ME, van der Breggen R, Sarasqueta AF, Koning F, de Miranda 
NFCC. A 40-marker panel for high dimensional characterization of cancer 










published: 04 June 2019
doi: 10.3389/fimmu.2019.01255
Frontiers in Immunology | www.frontiersin.org 1 June 2019 | Volume 10 | Article 1255
Edited by:
Michael A. Caligiuri,




Luxembourg Institute of Health (LIH),
Luxembourg
Vincent Vieillard,






This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 03 December 2018
Accepted: 17 May 2019
Published: 04 June 2019
Citation:
Stiglund N, Strand K, Cornillet M,
Stål P, Thorell A, Zimmer CL,
Näslund E, Karlgren S, Nilsson H,
Mellgren G, Fernø J, Hagström H and
Björkström NK (2019) Retained NK
Cell Phenotype and Functionality in
Non-alcoholic Fatty Liver Disease.
Front. Immunol. 10:1255.
doi: 10.3389/fimmu.2019.01255
Retained NK Cell Phenotype and
Functionality in Non-alcoholic Fatty
Liver Disease
Natalie Stiglund 1, Kristina Strand 2,3, Martin Cornillet 1, Per Stål 4,5, Anders Thorell 6,7,
Christine L. Zimmer 1, Erik Näslund 7, Silja Karlgren 7, Henrik Nilsson 7, Gunnar Mellgren 2,3,
Johan Fernø 2,3, Hannes Hagström 4,5 and Niklas K. Björkström 1*
1Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital,
Stockholm, Sweden, 2Hormone Laboratory, Haukeland University Hospital, Bergen, Norway, 3Mohn Nutrition Research
Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 4Department of Upper GI, Karolinska
University Hospital, Stockholm, Sweden, 5Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden,
6Department of Surgery, Ersta Hospital, Stockholm, Sweden, 7Department of Clinical Sciences, Danderyd Hospital,
Karolinska Institutet, Solna, Sweden
Non-alcoholic fatty liver disease (NAFLD), and the progressive stage non-alcoholic
steatohepatitis (NASH), is the predominant cause of chronic liver disease globally. As
part of the complex pathogenesis, natural killer (NK) cells have been implicated in the
development of liver inflammation in experimental murine models of NASH. However,
there is a lack of knowledge on how NK cells are affected in humans with this disease.
Here, we explored the presence of disease-specific changes within circulating and
tissue-resident NK cell populations, as well as within other major immune cell subsets, in
patients with liver biopsy-confirmed NAFLD. Using 18-color-flow cytometry, substantial
changes were observed in certain myeloid populations in patients as compared to
controls. NK cell numbers, on the other hand, were not altered. Furthermore, only minor
differences in expression of activating and inhibitory NK cell receptors were noted, with
the exception of an increased expression of NKG2D on NK cells from patients with NASH.
NK cell differentiation remained constant, and NK cells from these patients retain their
ability to respond adequately upon stimulation. Instead, considerable alterations were
observed between liver, adipose tissue, and peripheral blood NK cells, independently
of disease status. Taken together, these results increase our understanding of the
importance of the local microenvironment in shaping the NK cell compartment and stress
the need for further studies exploring how NASH affects intrahepatic NK cells in humans.
Keywords: natural killer cells, liver immunology, adipose tissue immunology, NAFLD, obesity
INTRODUCTION
NK cells are an important part of innate immunity where they participate in the defense against
viral infections and in tumor surveillance (1) Upon activation, NK cells perform cytotoxicity by the
release of cytolytic granules. They can also contribute to a pro-inflammatory environment through
the production of cytokines and chemokines such as interferon-γ (IFN-γ) and tumor necrosis
factor (TNF) (1). As part of the innate immune system, NK cells were believed to retain a static
phenotype during their life span with little evidence of differentiation except for transition from
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CD56bright to CD56dim NK cells (2). However, this view has
been revised in the last decade and it is now clear that NK cells
gradually undergo directed differentiation even after they have
reached the CD56dim stage (2). In addition to their presence
in the circulation, NK cells are found in numerous peripheral
tissues and are especially enriched in the liver and uterus where
they comprise up to 30 and 45%, respectively, of all lymphocytes
(3, 4). However, compared to circulating NK cells, less is known
regarding NK cells residing in tissues. In relation to the liver,
studies have in recent years shown the importance of NK cells
in the pathogenesis and clearance of chronic viral hepatitis
infections in humans (5). However, the role of NK cells in many
other liver diseases remains elusive.
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease worldwide. A sub-group of
NAFLD patients develop chronic inflammation in the liver,
which over time can lead to liver fibrosis. This stage of the
disease is known as non-alcoholic steatohepatitis (NASH) (6)
and these patients are at risk of developing liver cirrhosis,
liver failure, and hepatocellular carcinoma (HCC) (7). The
increased rates of obesity in many countries has contributed
to the drastic global increase in NAFLD prevalence in recent
years (8). Thus, NAFLD complications, such as NASH, liver
cirrhosis, and HCC, are posing a significant challenge to health
care systems worldwide (6). Several theories exist as to why
liver inflammation develops in patients with NAFLD. In more
detail, disease development is believed to be influenced by an
interplay between genetic and environmental factors, ranging
from disturbances in lipid storage and metabolism, changes in
dietary patterns and microbiota, to perturbed immune activation
(6). However, the exact mechanisms as to why some patients
progress in their disease whilst others do not still remain elusive.
Interestingly, murine models have revealed the importance
of innate immunity, and in particular NK cells, during NASH-
development (9). Many NK cell ligands are up-regulated in
the liver of mice with NASH and this is followed by influx of
activated cytotoxic NK cells (10, 11). Furthermore, NK cells can,
via Tumor necrosis factor (TNF)–related apoptosis-inducing
ligand (TRAIL) production, promote a pro-inflammatory state
in the steatotic liver and by this mechanism contribute to
progression toward steatohepatitis (10). In addition, NK cell
activation in response to IL-15 promotes NASH-development
in mice (12) and NK cells are also thought to play an
important role in regulating fibrosis development in NASH
(13, 14). In addition, obesity itself can also alter NK cell
phenotype, metabolism, and function (15–18). Indeed, several
recent studies in mice have suggested NK cells to be important
Abbreviations: ALT, alanine transferase; AST, aspartate transferase; BMI, body
mass index; HCC, hepatocellular carcinoma; HOMA-IR, homeostatic model
assessment; HSC, hepatic stellate cell; IFN-γ, interferon-gamma; IL, interleukin;
ILC1, innate lymphoid cell group 1; KIR, killer cell immunoglobulin-like
receptor; MAIT, mucosa-associated T; mDC, myeloid dendritic cell; NAFL, non-
alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic
steatohepatitis; NAS, NAFLD activity score; NK, natural killer; PBMC, peripheral
blood mononuclear cell; pDC, plasmacytoid dendritic cell; SDI, Simpson diversity
index; SNE, stochastic neighbor embedding; TRAIL, TNF-related apoptosis-
inducing ligand; TNF, tumor-necrosis factor.
for development of insulin resistance (19–21). However, there
is a lack of knowledge on how NK cells are affected in
humans with NASH, both with respect to circulating NK cells
as well as to NK cells residing in metabolically active tissues
such as liver and adipose tissue. To address this, we here
performed an in-depth phenotypic and functional analysis of
circulating NK cells in NAFLD patients as well as explored




Several clinical cohorts were included in the current study.
All studies were approved by the regional ethics committee
in Stockholm (Dnr’s: 2010/678-31/3, 2006/971-31/1, 2006/229-
31/3, and 2014/979-31/1) and oral and written informed consent
was obtained from all participants. First, peripheral blood
samples were obtained from 26 patients with liver biopsy-
confirmed NAFLD from the out-patient clinic at the Upper GI
Tract Department, Karolinska University Hospital, Stockholm,
Sweden. SeeTable 1 for detailed patient characteristics. Secondly,
as controls, peripheral blood from 15 healthy blood donors
was collected from the blood bank at the Karolinska University
Hospital, Stockholm, Sweden. Inclusion criteria in controls
were normal body-mass index (BMI), normal liver enzymes
[alanine aminotransferase (ALT) and aspartate aminotransferase
(AST)], and no history of type 2 diabetes. Thirdly, in order
to assess tissue resident NK cells, peripheral blood as well
as liver and adipose tissue biopsies were collected from 26
patients undergoing laparoscopic gastric bypass surgery for
morbid obesity at Danderyd and Ersta Hospitals in Stockholm.
All patients had a BMI above 35 and had no previous
history of liver disease. Included patients were not prescribed
any low-calorie pre-surgery diet since this would influence
degree of liver steatosis and possibly liver inflammation. A
fraction of obtained liver biopsies was used for clinical scoring
of liver histology according to the NAFLD activity score
(NAS) and fibrosis stage. Based on the severity of the liver
histology, patients were divided into three groups; patients with
normal liver histology, patients with liver steatosis only (non-
alcoholic fatty liver, NAFL), and patients with liver inflammation
(NASH). See Table 2 for more detailed characteristics on this
patient cohort.
Isolation of PBMC From Blood Samples
Peripheral blood mononuclear cells (PBMC) were isolated
from blood samples using density gradient centrifugation.
Briefly, whole blood was diluted with phosphate buffered saline
(PBS; Invitrogen, USA), carefully layered on top of Ficoll-
Hypaque (GE Healthcare, UK), and centrifuged. The leukocyte
layer was extracted, carefully washed, and cryopreserved in
freezing medium [90% heat-inactivated fetal bovine serum
(FBS; Sigma-Alderich, USA) and 10% dimethyl sulfoxide
(DMSO; Life Technologies)] until flow cytometry experiments
were performed.
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Subjects 15 11 15
Age, mean (years) 54 56 58
Male, n 10 (67%) 8 (73%) 9 (60%)
Female, n 5 (33%) 3 (27%) 6 (40%)
BMIc mean (kg/m2 ) 24 35 31
ALTd, mean (µkat/L) NA 0.51 0.75
NAFLD Activity Score, median (range) NA 3 (1–4) 5 (5–7)
Steatosis (0–3), median (range) NA 1 (1–2) 2 (1–3)
Lobular inflammation (0–3), median (range) NA 1 (1–3) 2 (1–3)
Hepatocyte ballooning (0–2), median (range) NA 0 (0–1) 2 (1–2)





eFibrosis score according to Kleiner et al. (22).
NA, not applicable.
TABLE 2 | Bariatric surgery cohort characteristics.
Non-NAFLD NAFLa NASHb
Subjects 8 10 5
Age (year), mean 43 45 43
Male 1 (12.5%) 3 (30%) 0 (0%)
Female 7 (87.5%) 7 (70%) 5 (100%)
BMIc, mean (kg/m2) 37 37 37
ALTd (µkat/L), mean 0.37 0.51 0.75
P-Insulin (IUe), mean 14.3 19.8 36.0
P-Glucose (mmol/L), mean 5.6 6.4 6.5
HOMA-IRf, mean 3.6 5.7 10.5
NAFLD Activity Score, median (range) 0 (0) 3.5 (1–4) 5 (5)
Steatosis (0–3), median (range) 0 (0) 1 (1–3) 2 (1–2)
Lobular inflammation (0–3), median (range) NA 1 (0–2) 2 (1–2)
Hepatocyte ballooning (0–2), median (range) NA 1 (0–2) 1 (1–2)






fHomeostatic model assessment—insulin resistance.
gFibrosis score according to Kleiner et al. (22).
Isolation of Immune Cells From Liver and
Adipose Tissue
The core liver biopsies were collected during surgery directly into
complete cell medium [Hyclone RPMI (Invitrogen), 10% FBS,
and 1mM L-glutamine (Invitrogen)] and kept on ice until same-
day processing. Tissue pieces were mechanically dissociated,
followed by enzymatic digestion in collagenase II for 30min
at 37◦C, and filtered through a 100µm filter, before flow
cytometry staining.
Antibody Staining Protocol
Cryopreserved PBMC were thawed in a 37◦C water bath,
immediately transferred to cell medium, washed, and
resuspended in complete cell medium. Three million PBMC
were stained in each test. Flow cytometry primary and secondary
stainings were performed in flow buffer (PBS with 2mM EDTA
and 2% FBS) for 20min in the dark at room temperature.
After staining, cells were fixed for 15min in the dark at
room temperature using the Fix/Perm solution (eBioscience,
USA). Finally, Fix/Perm solution was washed away, cells were
resuspended in flow buffer, and kept at 4◦C in the dark until they
were acquired on the flow cytometer. For intracellular stainings,
cells were permeabilized in Fix/Perm solution for 45min and
then stained for 30min in permeabilization buffer (eBioscience,
USA), diluted 1:10 with MQ water, before being washed and
analyzed. All samples were run on an 18-color LSRFortessa
(BD Biosciences, USA) equipped with 355, 405, 488, 561, and
639 nm lasers.
Functional Experiments
NK cell degranulation and cytokine production were assessed
by co-culture experiments with target cells. PBMCs were pre-
stimulated overnight with IL-12 (10 ng/ml, Peprotech) and IL-18
(100 ng/mL, Medical & Biological Laboratories) and then K562
cells were added at a 1:10 ratio. One hour after addition of
target cells, Golgi plug (Brefeldin A, BD Biosciences) and Golgi
stop (Monesin, BD Biosciences) were added and the assay was
continued for an additional 5 h. NK cells were then stained for
analysis using flow cytometry.
Microscopy
Liver biopsy specimens obtained fromNAFL/NASH patients and
patients undergoing gastric bypass surgery were stained with
hematoxylin and eosin and graded in a blinded fashion by an
experienced hepatologist according to the NAFLD activity score
(NAS) (23). In addition, liver biopsies were stained with Sirius
red to evaluate liver fibrosis and scored according to Kleiner on a
0–4 scale (23).
Flow Cytometry Analysis
To avoid bias from intra-experimental variability that could affect
the flow cytometry analysis, samples from both healthy donors
and patients were analyzed in each experiment. Acquired data
was compensated using a compensation matrix generated based
on antibody-stained control beads and analyzed using FlowJo
Version 9.6.4 (Treestar, USA). Apart from conventional flow
cytometry analysis, Barnes-Hut stochastic neighbor embedding
(SNE) analysis, using an in-house built script (24) in R (The
R Foundation for Statistical Computing), was performed in
order to visualize potential differences not present in two-
dimensional space. For SNE-analysis, 1,000 CD56dim NK cells
or 500 CD56bright NK cells from each donor was included. The
data was clustered based on median fluorescence intensity (MFI)
of the following markers: CD16, CD25, CD44, CD49a, CD56,
CD57, CD69, CD107a, HLA-DR, IFN-γ, KIRs, MIP-1β, NKG2A,
NKG2C, and TNF.
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Staining of Primary Hepatocyte
Primary human hepatocytes were isolated from three organ
donors whose livers were not used for liver transplantation,
acquired from the Karolinska University Hospital, using a
protocol previously described (25). The cells were then stained
fresh with antibodies against MICA, MICB, HLA-ABC, CD155,
ULBP-1, ULBP-2, and ULBP-3 conjugated with PE and analyzed
on a BD FACS Accuri.
Quantification of Soluble MICA and MICB
by ELISA
MICA and MICB solid-phase sandwich ELISAs (enzyme-
linked immunosorbent assay, Thermofisher) were performed
according to the manufacturer instructions. Briefly, human sera
were incubated 2, 5, and 2 h respectively diluted two times
in provided buffers (capture phase). After washing, biotin-
conjugated anti-MICA and MICB antibodies were incubated for
1 h and streptavidin-HRP was added after washing. Unbound
streptavidin-HRP was removed by washing and substrate
solution reactive with HRP was added. The reaction was stopped
by acid after 30min and absorbance measured at 450 nm.
Statistical Analysis
Data were analyzed using Prism Version 6.0 b (GraphPad
Software Inc.; USA). The Mann–Whitney U-test or t-tests were
used depending on if data sets were normally distributed, using
D’Agostino-Pearson omnibus normality test. The threshold for
statistical significance was set to α < 0.05. For analysis of NK
cell population diversity, Simpson Diversity Index (SDI) was
calculated as previously described (26).
RESULTS
Global Assessment of Immune Cells in
NAFL and NASH
To determine the impact of NAFL and NASH on the peripheral
blood immune cell compartment, a broad profiling of major
lymphoid and myeloid immune cells in patients and controls
was initially performed (Figure 1A). Whereas, few differences
were noted among CD4, CD8, and γδ T cells, a trend toward
a decline in MAIT cells was observed in NASH patients as
compared to NAFL patients and healthy controls (Figure 1B). A
decrease of MAIT cells in NASH is in line with recent literature
(27). Regarding NK cells, neither frequency (Figure 1B) nor
absolute numbers (data not shown) were affected by the presence
of obesity, NAFL, or NASH. With respect to the myeloid
immune cell compartment few differences were observed for
monocytes andmyeloidDCs. However, a decline in the frequency
of plasmacytoid DCs (pDCs) was noted in NASH patients
(Figure 1C). Also, the absolute numbers of pDCs were decreased
and the loss of pDCs correlated inversely with the degree
of liver damage measured as serum alanine transferase levels
(Figure 1C). Taken together, although alterations could be
observed in certain innate immune cell subsets, the overall size of
the peripheral blood NK cell compartment remained unaltered in
NAFL and NASH.
Upregulation of NKG2D on NK Cells From
NASH Patients
Since NK cells are far from a homogeneous population, a
more in-depth immune-phenotyping of activating and inhibitory
receptors on circulating NK cells was performed. The CD56dim
to CD56bright NK cell relationship was unaffected in NAFL
and NASH (Figures 2A,B). Next, we simultaneously assessed
expression of 12 surface and intracellular markers on the NK
cells (Figure 2C). As expected, CD56dim NK cells expressed
higher levels of NKG2C, KIRs, and CD57, while CD56bright
NK cells had a higher expression of NKG2A, CD161, CD44,
and NKp46 (Figures 2C,D). Surprisingly, neither the degree of
NAFLD disease severity (Figure 2D) nor presence of obesity
(data not shown) had a detectable effect on the NK cell
receptor repertoire on circulating NK cells, with the exception
for expression of the activating receptor NKG2D. In more detail,
both CD56bright and CD56dim NK cells from patients with NASH
expressed significantly higher levels of NKG2D on their surface
(Figures 2E,F). This was also observed when comparing normal
weight with obese individuals (Figure 2G). However, since NK
cells from NAFL patients had close to normal levels of NKG2D
(Figure 2F), this would suggest that increased expression of
NKG2D primarily associated with NASH. Furthermore, this
increase was specific to NK cells since it was not observed on
T cells from the same patients (data not shown). To dissect
the role of NKG2D more in-depth in relation to the liver and
NAFL we assessed presence of NKG2D-ligands. No difference
in levels of soluble MICA and MICB was noted in patients as
compared to controls (data not shown). Furthermore, primary
human hepatocytes from healthy organ donors were negative for
NKG2D-ligands whereas CD155 and HLA class I was expressed
(Supplementary Figure 1).
Finally, we assessed NK cell differentiation, as determined
by the expression of NKG2A, KIRs, and CD57, as well as NK
cell diversity by calculating Simpson diversity index (SDI) (28,
29). However, both of these metrics for NK cell compartment
composition remained unaltered in NAFL and NASH patients
as compared to healthy controls (Figures 2H,I). In summary,
the phenotype of the circulating NK cell population remains
unaffected by NAFL and NASH with the exception of NKG2D
being upregulated in patients with NASH.
Functional Capacity of Peripheral NK Cell
Subsets in NAFL and NASH
Having determined the NK cell phenotype in peripheral blood,
we next evaluated the functional capacity of NK cells in NAFL
and NASH. To this end, NK cells were stimulated with cytokines
(IL-12+IL-18) and/or K562 target cells and production of IFN-
γ, TNF, MIP-1β, upregulation of CD107a, CD69, CD44, and
CD25, as well as downregulating of CD16 as a consequence of
activation was measured using flow cytometry (Figure 3A). As
expected, stimulation with cytokines led to high levels of IFN-γ
being produced as well as strong upregulation of CD25 and CD69
whereas K562 cell stimulation yielded a robust degranulation
response and elevated levels of TNF and MIP-1β (Figures 3A,B).
When assessing single functional responses, NK cells from
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FIGURE 1 | Immunophenotyping of major peripheral blood immune cell subsets in NAFL and NASH. (A) Flow cytometry gating scheme used to identify the
investigated immune cell subsets. Arrows indicate the sequence of gating. (B) Summary data for the frequency out of total leukocytes for the indicated immune cell
populations in healthy controls (n = 10), NAFL (n = 4), and NASH (n = 11) patients. (C) Summary data of pDC frequency out of total leukocytes (left), absolute
counts of pDCs (middle), and correlation between pDC frequency and ALT (right) in the indicated patient groups. Bars in (B,C) represent mean and error bars show
SEM. **p < 0.01.
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FIGURE 2 | Phenotypic characterization of circulating NK cells from NAFLD patients. (A) Representative flow cytometry plots of NK cells from healthy, NAFL, and
NASH patients. (B) Frequency of CD56bright NK cells out of total NK cells in peripheral blood of healthy controls (n = 13), NAFL patients (n = 9), and NASH patients (n
= 16). (C) Representative histograms for the indicated markers on CD56bright and CD56dim NK cells as well as internal negative control. The plots represent stainings
from one healthy donor. (D) Heat map depicting the mean frequency of NK cells expressing CD16, CD44, CD57, KIRs, NKG2A, and NKG2C as well as the mean MFI
of CD69, NKp46, CD161, Eomes, T-bet, and NKG2D on CD56dim and CD56bright NK cells for the indicated groups. (E) Representative histogram of NKG2D
(Continued)
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FIGURE 2 | expression on NK cells from healthy control, NAFL, and NASH patients respectively. (F,G) Scatter plots of NKG2D MFI on CD56dim and CD56bright NK
cells from the indicated groups. In (F), healthy controls (n = 11), NAFL (n = 6), and NASH (n = 13) patients, in (G) healthy controls (n = 11), obese individuals (n = 18).
(H) Bar graph showing the frequency of CD56dim NK cells that express different combination of NKG2A, KIRs, and CD57. Black circles indicate presence of the
marker and white circles no expression. (I) Inverse Simpson Diversity index (SDI) analysis for healthy (n = 11), NAFL (n = 7), and NASH patients (n = 12). The
Mann–Whitney U-test was used for comparison between groups. Bars in (B,F,G,I) show mean, error bars in H represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
patients with NASH had a similar capacity to degranulate,
produce cytokines, and upregulate activation markers as their
NAFL counterparts and the healthy controls (Figure 3B). Also,
the ability of NK cells to performmultiple functions was retained
in both NAFL and NASH patients as compared to healthy
controls (Figure 3C).
The NK cell compartment consists of many different
subpopulations and NK cells can produce a multitude
of functions in a variegated fashion. Although single or
multifunctional analysis of NK cell functional responses revealed
no considerable alterations in function when comparing NASH
with healthy controls it is plausible that functional difference
might exist in multivariate space not allowing identification
by conventional flow cytometry gating. To address this, we
performed a SNE analysis of the NK cell functional responses
and first generated SNE maps of responding compared to non-
responding NK cells (Figure 3D). These SNE maps segregated
considerably (Figure 3D, residual map) and by projecting the
differences onto the single parameters that formed the basis of the
SNE map the pattern of NK cell responses in multidimensional
space could be revealed (Figure 3D, lower panels). In more detail
this shows how certain NK cell subpopulations responded with
many functions and others only with single function. Together,
this validated the analysis approach and allowed us to compare
patients with healthy controls (Figure 3E and data not shown).
Although the residual plots revealed difference when comparing
responding NK cells from healthy controls with NAFL or NASH
patients (data not shown) or NAFL patients with NASH patients
(Figure 3E), these differences could not be attributed to a
specific phenotype when the residual plot was projected onto the
single parameters (data not shown). This suggests that also in
multi-dimensional space, the NK cell response was unaltered in
NAFL and NASH.
Characterization of NK Cells in Adipose
and Liver Tissue
To this end, characteristics of circulating NK cells have been
analyzed. However, NAFL and NASH are diseases of the liver and
also tightly coupled to obesity, adipose tissue dysregulation, and
reduced insulin sensitivity. Thus, the analysis was focused on NK
cells from liver and adipose tissue. In line with previous literature
(9), NK cells were enriched in the liver compared to peripheral
blood (Figures 4A,B) and a sizeable population of NK cells could
also be detected in visceral adipose tissue. Furthermore, both
types of investigated tissue had a skewing in the distribution of
CD56bright andCD56dim NK cells as compared to circulation with
CD56bright NK cells representing up to half of all NK cells in liver
and adipose tissue (Figure 4B). Also, whereas the differentiation
status of adipose tissue NK cells, with respect to expression of
NKG2A, KIRs, and CD57, mirrored that of circulating NK cells,
differences were observed especially within liver CD56dim NK
cells in expression of these markers (Figures 4C,D).
SNE-analysis of the NK cell compartment identified that
NK cells derived from liver and adipose tissue displayed a
unique phenotype compared to peripheral blood NK cells
(Figure 4E). The major distinction between NK cells derived
from circulation and NK cells derived from tissues was
a higher expression of the tissue residency marker CD69
(Figure 4E). As a consequence of liver and adipose tissue
containing larger populations of CD56bright NK cells, the SNE
analysis also identified higher expression of NKp46, NKG2A,
and CD56 but lower expression of CD16, CD57, and KIRs
within the population enriched in the tissues compared to
in circulation (Figure 4D). This is in line with the overall
phenotypic differences observed when comparing CD56bright
with CD56dim NK cells (Figures 2C,D). Finally, we confirmed
expression of tissue residency markers on liver and adipose
tissue by conventional flow cytometry gating (Figures 4F,G). As
expected, the expression was primarily confined to the CD56bright
NK cells. Interestingly, while CD69 was highly expressed in
both liver and adipose tissue, CD49a was only found on a
small fraction of CD56bright NK cells in the liver whereas
higher expression was noted in adipose tissue (Figures 4F–H).
These results highlight the importance of the organ-specific
microenvironment in shaping the local NK cell population
and emphasize the importance of studying the tissue-resident
compartment when trying to understand the pathogenesis of
diseases affecting peripheral organs.
The Phenotype of Tissue NK Cells Remains
Unaltered in NAFL and NASH
Finally, we assessed the impact of NAFL and NASH disease stage
and severity on the frequency and phenotype of liver and adipose
tissue NK cells (Figure 5). Patients where data on tissue NK
cells were available were stratified based on NAS score (non-
NAFL which represented no steatosis present, NAFL, NASH),
liver fibrosis (fibrosis score 0–1 vs. 2–3), and insulin sensitivity
status (HOMA-IR <4.5 vs. >4.5). Although NK cells were
more abundant in liver (Figure 4B) their frequency remained
unaffected by clinical stage (Figure 5C). Also, the frequency of
NK cells in adipose was unaltered by NAFLD disease activity,
level of fibrosis, and insulin sensitivity (Figure 5C). Finally, the
NK cell phenotype was assessed. Since CD16− and CD16+
NK cells display distinct phenotypes (Figures 2C,D, 4E–G),
these were analyzed separately. For none of the investigated
phenotypic markers, a clear link to the clinical parameters could
be observed (Figure 5D).
Thus, whereas murine models suggest NK cells to play a
distinct role in NAFL andNASH, both the human circulating and
Frontiers in Immunology | www.frontiersin.org 7 June 2019 | Volume 10 | Article 1255
Stiglund et al. NK Cells in NASH
FIGURE 3 | Retained functional capacity of circulating NK cells in NAFLD. (A) Representative concatenated flow cytometry plots showing CD56dim NK cell responses
following the indicated stimulations. (B) Heat map summarizing the mean frequency of responding NK cells for the measured functions and indicated stimulations in
healthy controls (n = 15), NAFL patients (n = 10), and NASH patients (n = 16). (C) Multifunctional analysis of the combination of degranulation (CD107a) and cytokine
production (IFN-γ, MIP-1β, and TNF) responses for IL-12 + IL-18 stimulation and/or co-culture with K562 target cells. (D) SNE plots of total cells from healthy donors
subsequently divided in stimulated and un-stimulated cells. The residual plot highlights the decreased (blue) or more highly expressed (red) areas in the stimulated
cells. Underneath, individual plots of the expression of 15 single markers are shown. (E) SNE plots depicting the difference between CD56dim (left) and CD56bright
(right) NK cells from NAFL and NASH patients after IL-12 + IL-18 + K562 stimulation where the density plots highlight the specific changes in NASH patients.
peripheral tissue NK cell compartments remain largely intact in
these diseases.
DISCUSSION
NAFLD is the most common chronic liver disease worldwide
and a subgroup of NAFLD patients develop chronic liver
inflammation (NASH) with ensuing fibrosis and increased
risk for HCC. Since little is known regarding NK cells
in this disease and because NK cells are highly enriched
in human liver, we here performed an extensive mapping
of the NK cell compartment in NAFL/NASH using high-
dimensional flow cytometry technology. We assessed the
imprint of liver inflammation in NASH on circulating NK
cells and show specific upregulation of the activating receptor
NKG2D. In addition, by employing bariatric surgery as a
human model, we also comprehensively mapped both liver and
adipose tissue NK cells revealing substantial differences in NK
cell population composition in-between tissues. However, no
significant differences in the tissue-resident NK cell populations
in patients with and without NAFL/NASH were detected.
NK cells have previously been investigated in other chronic
liver diseases, especially in chronic viral hepatitis. These studies
revealed that NK cells have decreased function in chronic
hepatitis C (5, 30, 31). In obese individuals, decreased NK cell
functionality combined with increased activation was reported
(15, 16). A recent study showed that this reduced functionality
was a result of metabolic paralysis of NK cells (18). However,
our study detected no functional defects or changes in activation,
despite both the in-depth and broad evaluation performed.
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FIGURE 4 | Phenotype of NK cells in liver and adipose tissue. (A) Representative flow cytometry plots of NK cells derived from blood, liver, and adipose tissue.
(B) Scatter plot of the frequency of total NK cells out of viable leukocytes and CD16− NK cells out of total NK cells in peripheral blood, liver, and adipose tissue. PBMC
(n = 22), adipose tissue (n = 19), and liver (n = 15). (C) Representative concatenated flow cytometry plots showing expression of differentiation markers NKG2A,
KIRs, and CD57 on CD16− or CD16+ NK cells in blood, liver, and adipose tissue. (D) Bar graphs showing frequency of cells expressing the indicated differentiation
markers in CD16− or CD16+ NK cells from blood, liver, and adipose tissue. PBMC (n = 22), adipose tissue (n = 19), and liver (n = 15). (E) SNE plot of total NK cells
from adipose tissue (left) or liver (right) compared to peripheral blood. The residual plot highlights the decreased (blue) or more highly expressed (red) areas within
tissue NK cells. (F,G) Representative flow cytometry plots showing CD69 and CD49a expression on total NK cells from the indicated tissues. (H) Expression of CD69
and CD49a on CD16− and CD16+ NK cells in peripheral blood, liver, and adipose tissue. In H, CD69 on PBMC (n = 22), adipose tissue (n = 18), and liver (n = 15),
CD49a on PBMC (n = 9), adipose tissue (n = 9), and liver (n = 7). Bars in (B,D,H) represent mean and error bars in (D,H) show SEM. **p < 0.01, ***p < 0.001.
These discrepancies might in part be based on methodological
dissimilarities between the studies, with different target cells
used but also on differing patient inclusion criteria. Indeed,
our patients had, in general, mild fibrosis, with no patients
suffering from cirrhosis, suggesting a more active inflammatory
disease. This compared to other studies where many patients
had cirrhosis (14) or higher BMI (15). Michelet et al identified
functional defects as well as the loss of CD56bright NK cells in
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FIGURE 5 | Tissue NK cells in relation to patient disease characteristics.
(A) Representative hematoxylin and eosin stainings on normal, NAFL, and
NASH liver sections. (B) Distribution of the patients in relation to age, BMI, and
levels of alanine transferase (ALT) as a proxy for liver damage. (C) Heat map
showing mean frequency of total, CD16+, and CD16− NK cells for the
indicated groups. (D) Heat map showing mean frequencies of NKG2A, CD57,
KIRs, NKG2C, CD69, and CD49a expression on CD16− and CD16+ NK cells
for the indicated groups. *p < 0.05.
obese patients (18). This is in line with a previous report (15),
and common of these two studies was that included patients had
BMI’s of up to 50. Our cohort had a considerably lower average
BMI of around 35. Together, this suggests that the functionality of
NK cells and NK cell subset composition is retained in less severe
obesity whereas alterations become evident in patients with
morbid obesity. Atherosclerosis, hypertension, and adipose tissue
inflammation are common comorbidities in NAFLD patients and
thus potential confounding factors that should be controlled for.
Our strategy to address this challenging issue was in one part to
stratify patients into NAFL or NASH by the use of liver biopsies,
considered the gold standard. In addition, we made a subgroup
analysis based on the level of fibrosis and on insulin sensitivity.
However, in none of these comparisons, neither in peripheral
blood nor in liver or adipose tissue, any profound disease-related
alterations in the NK cell populations could be observed. Of note,
we focused our analysis on the major two subpopulations of
NK cells: CD56bright and CD56dim NK cells. Apart from them,
there are additional un-conventional NK cell subset, such as
CD56−CD16+ and CD56dimCD16− NK cells (32), that should
be investigated in future studies.
A recent report demonstrated how chronic hepatitis C
irreversibly causes decreased receptor repertoire diversity in
circulating NK cells (26) Related changes have also been observed
in chronic hepatitis D (33). Based on this, we wanted to
investigate whether the chronic “non-infectious” inflammation
in NAFLD could cause a similarly reduced diversity. However,
NK cell repertoire diversity, determined by SDI, remained intact
in NAFLD. Both NAFLD and chronic viral hepatitis are slowly
developing liver diseases that take years to produce symptoms.
However, manymore changes in serum cytokines can be detected
in hepatitis C patients as compared to NASH patients (34) and it
is plausible that the general degree of inflammation in NASH is
more low-grade as compared to chronic viral hepatitis. Thus, it
might be that a larger inflammatory insult is needed in order to
affect NK cell repertoire diversity.
In experimental models, NK cells have been shown to protect
against liver fibrosis development, e.g., via NKp46-mediated
macrophage activation (13) or by killing of hepatic stellate
cells (HSCs) (35). Similar evidence exists in the human setting
but primarily in relation to chronic viral hepatitis and fibrosis
development (36). NKG2D is another NK cell surface receptor
that may be protective against fibrosis development in mice
by targeting activated HSCs (37). Furthermore, the NKG2D-
ligands MICA andMICB are both upregulated in NASH-livers in
mice (11). For NAFLD patients, level of fibrosis is an important
predictor of long-term survival (38, 39). Interestingly, we could
show that NK cells express higher levels of NKG2D in patients
with NASH. This upregulated NKG2D expression could be a
response to the increased hepatocyte stress, inflammation, and
apoptosis that can be seen in NASH-livers (23). To determine
if NKG2D influenced the degree of liver fibrosis in NAFLD
patients, we compared levels of fibrosis to NKG2D expression on
circulating NK cells but could not detect any association. This
could be due to the fact that fibrosis is a dynamic process that
occurs during many years in NAFLD. In the current study, we
did not have the possibility to investigate NKG2D expression on
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intrahepatic NK cells. Future studies should assess this and also
specifically evaluate the capacity of NK cells to target HSCs (or
hepatocytes) via NKG2D in NAFLD.
Apart from having a protective role in fibrosis development,
adipose tissue NK cells, or ILC1-like cells, have also been shown
to augment insulin resistance in experimental murine models
(19, 20, 40). In more detail, it has been proposed that NK
cells sense stressed cells in adipose tissue, respond with IFN-
γ production, in turn causing macrophage polarization toward
a pro-inflammatory phenotype, which subsequently leads to
insulin resistance (19, 20, 40). However, little is known about
human adipose tissue NK cells in general and also how they relate
to obesity, insulin resistance, and liver disease. In this regard, we
assessed visceral adipose tissue NK cell frequency and phenotype.
Adipose tissue contained a similarly large population of NK
cells as found in peripheral blood. However, adipose tissue was
clearly enriched for CD56brightCD16− NK cells expressing tissue
residency markers. This profile with enrichment of CD56bright
NK cells was similar to the phenotype of NK cells found in
matched liver samples and also to NK cells in many other
peripheral tissues in general (41). Interestingly, the specific subset
of adipose tissue NK cells (or ILC1-like cells) that contribute to
insulin resistance inmice express CD49a on their surface (21, 40).
We here report that also human adipose tissue contains NK cells
expressing CD49a. CD49a+ NK cells had a CD56brightCD16−
phenotype, which is different from liver CD49a+ NK cells (4),
and were more prevalent in adipose tissue as compared to liver
and peripheral blood. However, no link between the presence
and levels of adipose tissue CD49a+ NK cells and the presence of
insulin resistance was noted in the investigated patients. Within
the scope of this study, only CD49a and CD69 was studied
as tissue residency markers. There are a number of additional
surface markers as well as transcription factors that are linked to
tissue residency, which should be investigated in future studies.
Our study design, with liver and adipose tissue biopsies
acquired during laparoscopic surgery, enabled us to uniquely
study NK cells from different peripheral tissues within the
same individual. This analysis revealed interesting features,
emphasizing the different phenotypes of tissue-resident
cells from distinct tissues. We could show that NK cell
differentiation status differed not only between liver and
peripheral blood, in line with previous reports (41), but
also between liver and adipose tissue-derived NK cells. The
pattern of tissue residency marker expression was also distinct
between liver and adipose tissue NK cells within the same
individual. These data emphasize the importance of the
specific local microenvironment in influencing the shape of
the NK cell population. This also shows the importance of,
although cumbersome, studying tissue NK cells in different
human disorders.
Limitations of our study have also to be considered. First,
the target cell line used in the functional experiments consist of
the leukemia cell line K562. While being the gold standard for
assessment of NK cells function, due to its lack of MHC class
I, it is not representative for the NAFLD setting. However, it
does express NKG2D-ligands (42), which primary hepatocytes
derived from organ donors did not (Supplementary Figure 1).
Ideally, future studies should assess NK cell responsiveness
against primary target cells derived from livers of NAFLD
patients, such as hepatic stellate cells or hepatocytes. Second,
in addition to the target cells derived from NASH-livers, future
work should focus on the function of tissue-derived NK cells
since this study, due to practical reasons, only assessed the
function of circulating NK cells. Third, within the scope of
this study, NKG2D expression was only studied on NK cells
derived from peripheral blood. This might not be representative
of NKG2D expression on NK cells derived from liver and
adipose tissue. Fourth, this study does not address the NKG2D-
ligand expression in NASH livers which, in combination with
the NKG2D expression on hepatic NK cells, could provide
interesting insights into the disease mechanisms of NASH.
Thus, the exact role of NKG2D in NAFLD still remains to
be elucidated.
In summary, we here performed a comprehensive assessment
of peripheral blood and tissue NK cells in relation to NAFLD,
the most common chronic liver disease worldwide. Surprisingly,
despite a substantial literature from experimental model systems
suggesting a role for NK cells in NASH, we found a largely
intact NK cell compartment in the human setting. Instead,
our study reveals significant differences in composition of the
NK cell compartment between human peripheral tissues and,
thus, illustrates the importance of understanding the local
microenvironment in shaping the NK cell repertoire.
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